Original source text
Tenable Holdings, Inc. (TENB) Analyst/Investor Day Transcript Live financial news intelligence
Track market-moving stories before they get noisy
Real-time pulse of financial headlines curated from 5 premium feeds.
Latest market signal
English
Commodities
GOLD
185
SILVER
107
OIL
60
PLATINUM
5
PALLADIUM
2
COPPER
1
- FMP Stock News 50s ago
- FMP Forex News 4m ago
- CoinGecko News 4m ago
- FIO Stock News 3m ago
- Patria Stock News 3m ago
- Editorial rewrite 50s ago
- Asset sync 13m ago
Latest coverage
Market News Feed
Scan headlines quickly, then expand any story for source context.
| Details | Date | Content | Source |
|---|---|---|---|
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-05-22 19:50
2mo ago
|
Tenable Holdings, Inc. (TENB) Analyst/Investor Day Transcript | FMP Stock News | |
|
|
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-09 09:00
1mo ago
|
Tenable Unveils AI-Powered Cloud Detection and Response Capabilities | FMP Stock News | |
|
Original source text
New threat detection and response capabilities reduce investigation time and mean time to remediation by transforming disjointed alerts into precise action June 09, 2026 09:00 ET | Source: Tenable Holdings, Inc.COLUMBIA, Md., June 09, 2026 (GLOBE NEWSWIRE) -- Tenable® Holdings, Inc. (NASDAQ: TENB), the exposure management company, today announced new AI-powered cloud threat detection capabilities that extend the Tenable One Exposure Management Platform, enabling security teams to prioritize and remediate the exposures attackers are actively targeting. As part of Tenable One, Tenable One Cloud Exposure correlates runtime telemetry with deep exposure context, transforming threat investigations and empowering teams to reduce risk before attacks impact the business. Static defenses cannot keep up with attackers who have weaponized AI, collapsing the exploit window from months to hours. Compounding the issue, fragmented security tools leave organizations overwhelmed with alerts while struggling to identify which risks require immediate action. Without intelligent correlation and prioritization, security teams burn critical cycles on endless triage, rather than reducing the exposures most likely to lead to compromise. Tenable addresses these operational inefficiencies by bridging the gap between cloud threat activity and unified risk visibility for proactive exposure management. Tenable goes beyond static misconfigurations and vulnerabilities, contextualizing runtime telemetry within the broader attack surface, empowering security teams to stop chasing theoretical risks and prioritize remediation based on true business impact. Tenable One Cloud Exposure delivers a new way to respond to threats with AI-powered threat stories, an AI-driven investigation layer that automatically correlates related detections across time, identity and cloud resources, transforming hundreds of raw alerts into a clear narrative of how an attack unfolded. Validated against near-real-time exposure context and risk insights, threat stories give defenders a clear, prioritized picture of what happened, what's at risk and where to act first. Tenable One Cloud Exposure expands enterprise-wide risk visibility with new cloud detection and response (CDR) capabilities, including: Vulnerability Validation and Runtime: Uses active scanning to confirm cloud resources that are reachable from the internet, delivering validated exposure context that sharpens alert prioritization and reduces noise.Dual Coverage: Combines agentless, Tenable-authored detections with an optional eBPF runtime sensor, giving security teams comprehensive visibility across cloud workloads without sacrificing deployment flexibility or coverage.Guided Response with Tenable Hexa AI: As the agentic engine of Tenable One, Tenable Hexa AI is the intelligence layer that reasons across live exposure context, threat findings, and environment history to deliver a prioritized, actionable response plan, in plain language, at attacker speed. “Security teams don't need more alerts. They need to know which exposures are actually putting the business at risk,” said Eric Doerr, Chief Product Officer, Tenable. “By combining runtime cloud telemetry with the exposure intelligence already inside Tenable One, we're helping customers move from investigation to remediation faster and with greater confidence.” Check out the demo to see Tenable cloud detection and response. More information about Tenable’s cloud detection and response capabilities is available at: tenable.com/cloud-security/solutions/cloud-detection-and-response About Tenable Tenable® is the exposure management company, exposing and closing the cybersecurity gaps that erode business value, reputation and trust. The company’s AI-powered exposure management platform radically unifies security visibility, insight and action across the attack surface, equipping modern organizations to protect against attacks from IT infrastructure to cloud environments to critical infrastructure and everywhere in between. By protecting enterprises from security exposure, Tenable reduces business risk for over 40,000 customers around the globe. Learn more at tenable.com. Media Contact: Tenable [email protected] Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected capabilities, benefits, and performance of our Tenable One Exposure Management Platform, Tenable One Cloud Exposure (including cloud detection and response capabilities), and Tenable Hexa AI. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to the development, adoption and performance of new and unproven technologies and other factors described under "Risk Factors" in Tenable's most recent Annual Report on Form 10-K and subsequent reports filed with the SEC. Tenable undertakes no obligation to update these statements to reflect events occurring after the date hereof. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-05-12 19:50
2mo ago
|
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript | FMP Stock News | |
|
Original source text
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-05-15 20:14
2mo ago
|
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms | FMP Stock News | |
|
Original source text
3 Biotech Stocks That Could Benefit from the Patent CliffCRISPR Therapeutics NASDAQ: CRSP Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months.Speaking at a Bank of America fireside chat hosted by analyst Alec Stranahan, Kulkarni said the company’s first 11 years were centered on developing CASGEVY for sickle cell disease and beta thalassemia and bringing the therapy to patients. With that program now commercialized through partner Vertex, he said CRISPR Therapeutics is shifting more attention to a broader portfolio that includes cardiovascular, autoimmune, oncology and rare disease programs. Get CRISPR Therapeutics alerts: CRISPR Therapeutics Gains After Earnings as Pipeline Hope GrowsKulkarni said the company expects six assets to generate data in the next 12 to 18 months. He described the pipeline as including CTX310, an ANGPTL3-targeting program for LDL cholesterol and triglyceride reduction; zugo-cel, an allogeneic CAR T cell therapy being developed for autoimmune disease and oncology; CTX611, a long-acting siRNA approach to blood thinning; CTX340, a hypertension program targeting angiotensinogen; an Lp(a) program; and an alpha-1 antitrypsin rare disease program. CASGEVY Launch Gains Momentum, CEO Says Kulkarni said CASGEVY’s commercial rollout is “gaining a lot of momentum,” though he emphasized that the launch differs from a typical pharmaceutical launch because of the time required between patient initiation, cell collection, manufacturing, infusion and revenue recognition. CRSPR Stock Could Be Ready to Deliver on Its Massive PromiseHe said Vertex, which is leading commercialization, initiated about 100 patients in 2024, more than 300 patients in 2025 and has now initiated more than 500 patients. Kulkarni said the growth in patient initiations should translate into future revenue as patients move through the treatment funnel, though he noted there can be a lag of two to three quarters from initiation to revenue recognition. “It’s a certainty that it all falls through because you’re not seeing patients drop out of the journey,” Kulkarni said. “It’s just a matter of time.” Stranahan noted that CASGEVY generated $43 million in the first quarter. Kulkarni said CRISPR Therapeutics does not see major headwinds for the product at this stage and said Vertex is executing well on supply chain and patient handling. He said the company feels “comfortable about the trajectory of the product.” Pediatric Label and Reimbursement Seen as Tailwinds Kulkarni pointed to several potential tailwinds for CASGEVY, including a pediatric label expansion. The current U.S. label covers patients ages 12 and older, and the company has submitted for an expansion to patients ages 5 and older. Kulkarni said treating younger patients could help prevent vascular and organ damage associated with disease progression. He also said the pediatric expansion could bring more children’s hospitals into the treatment network, potentially increasing center activation and treatment velocity. Outside the United States, Kulkarni said CASGEVY is the only available option in certain markets. He also highlighted a reimbursement agreement in Germany, describing it as a significant achievement given prior challenges faced by a competitor in that market. Kulkarni also discussed “gentler conditioning” as a future potential expansion of CASGEVY’s life cycle. He said CRISPR Therapeutics has not provided guidance on when such an approach might be available, but said it could meaningfully broaden the addressable population if it achieves results comparable to the current busulfan conditioning regimen. Cardiovascular Programs Target Large Markets On CTX310, Kulkarni said the company presented data last year showing reductions of approximately 50% in LDL cholesterol or triglycerides after treatment. He said the therapy uses lipid nanoparticle delivery and described the early safety profile as favorable, with limited and self-resolving liver enzyme elevations observed. For homozygous familial hypercholesterolemia, Kulkarni said the regulatory bar could be relatively low if the therapy can show additional LDL reduction on top of agents such as PCSK9 inhibitors. For severe hypertriglyceridemia, he said CRISPR Therapeutics needs more patient data before engaging regulators on a potential registrational path. Kulkarni also discussed CTX340, which targets angiotensinogen for hypertension. He said a gene-editing approach could provide consistent blood pressure reduction, in contrast to therapies that may wear off toward the end of a dosing period. He said reducing systolic blood pressure by 10 to 15 millimeters of mercury could be clinically meaningful, while still allowing physicians to adjust other medications. Separately, Kulkarni said the company’s collaboration with Sirius Therapeutics on a Factor XI siRNA program reflects a “right tool for the job” approach. He said CRISPR Therapeutics does not want to permanently edit Factor XI because anticoagulation may be needed for defined periods or specific patient populations. He said the company sees potential indications including secondary stroke prevention, atrial fibrillation patients not eligible for DOACs and peripheral artery disease after revascularization. Zugo-cel Advances in Autoimmune Disease and Oncology Kulkarni described zugo-cel as a potential best-in-class allogeneic CD19 CAR T therapy, citing what he called autologous-like efficacy with the convenience and cost-of-goods profile of an allogeneic product. In oncology, he said CRISPR Therapeutics previously showed a nearly 70% complete response rate, with at least two patients beyond 12 months at the time of the data cut. The company is also studying zugo-cel in combination with the BTK inhibitor pirtobrutinib, based on evidence that BTK inhibitors may potentiate CAR T therapies. In autoimmune disease, Kulkarni said the company’s goal is to become a leading player. CRISPR Therapeutics has dosed patients in lupus, myositis and scleroderma through the AID-500 trial and has expanded into immune thrombocytopenia and warm autoimmune hemolytic anemia. He said the company has also opened an IND for neuroimmune indications, citing evidence that zugo-cel can enter the central nervous system and eliminate B cells in the spine or brain. Kulkarni said CRISPR Therapeutics had dosed 14 patients in its autoimmune program as of its first-quarter update and expects to provide additional updates as development progresses. About CRISPR Therapeutics NASDAQ: CRSPCRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes. Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Should You Invest $1,000 in CRISPR Therapeutics Right Now?Before you consider CRISPR Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list. While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-05-19 09:45
2mo ago
|
The Best Stocks to Invest $3,000 In Right Now | FMP Stock News | |
|
Original source text
Is your portfolio in need of a reload, if not an outright reset? If so, you're not alone. A volatile start to 2026 has pushed some investors into positions they might not actually want, while other investors are still on the sidelines waiting for a pullback that may never happen. Both are mistakes. The smartest investing move is still just buying and sticking with quality stocks for the long haul.With that as the backdrop, if you have $3,000 otherwise-idle bucks you're ready to put to work in the market, here's a closer look at three of your best bets right now. Image source: Getty Images. Roku Ironically, the very same streaming industry that Roku (ROKU +3.62%) helped bring the cable television industry to its knees now faces the same problem as its predecessor: There's too much cost for too much bundled content. Growth in customer headcount for the streaming business has stalled as a result, seemingly presenting a problem for Roku. Roku's role within the streaming industry, however, leaves it far less subject to this slowdown than it might seem. The company is primarily an intermediary, providing technology to help users consume video content. It earns money just by making this programming available on its platform, regardless of how much or how little consumers actually watch, or what they pay to watch. Today's Change ( 3.62 %) $ 4.33 Current Price $ 123.97 And it's the top-viewed choice in a couple of key markets, including Latin America and North America. In fact, industry research outfit Pixalate reports Roku's already-leading share of North America's connected-television market grew to 36% during the first quarter of this year, nearly double next-nearest Amazon's 19%. This growing reach is translating into a positive fiscal impact as well. Even if the streaming business itself is stagnating, Roku is finding a way to capture the growing amount of money being spent to sell this digital entertainment. Last quarter's platform revenue grew 28% year over year, with an equal mix of advertising and subscription revenue contributing to this progress. The company also continues to widen its profit margins, turning $85.7 million of Q1's total top line of $1.25 billion into net income, versus the year-earlier loss of $27.4 million -- a pace of progress analysts expect to persist at least through next year, as the streaming business matures around this company's tech. ServiceNow It makes superficial sense that ServiceNow's (NOW 2.37%) shares have halved since the middle of last year. That's when investors began second-guessing the steep valuations of some artificial intelligence stocks. At that time, its shares were still well up from their sizable gains logged in 2023 and 2024, leaving them more than a little vulnerable to this headwind. Today's Change ( -2.37 %) $ -2.44 Current Price $ 100.64 Sellers, however, have arguably overshot their target, creating an opportunity for investors who can take a step back and see the bigger picture. ServiceNow is a workflow solutions provider, meaning anyone can use its AI-powered software to automate redundant, taxing, or time-consuming tasks so employees can focus on more important, higher-level work. It's not the only name in the business. UiPath and Workday are competitors, along with a few other lesser-known players. ServiceNow enjoys a competitive advantage, however. That's its age. Launched in 2003, it was one of the very first names in the workflow automation business -- long before artificial intelligence dramatically improved such tech. Indeed, the company has not only had time to carve out more than its fair share of this market (before and after it incorporated AI into its apps), but it's also been able to help shape the industry it now leads. Other outfits are in the mix, but none have been able to dethrone the original powerhouse in the workflow business. The thing is, there's still much more upside to realize. A long-term outlook from Morningstar suggests the company's revenue will grow from 2025's $13.3 billion to $29.5 billion in 2030, driving per-share profits up from $1.67 to $5.01 during this same stretch. That's annualized bottom-line growth of nearly 25%, more than justifying the valuation that seemed to worry so many investors in the latter half of last year. CRISPR Therapeutics Finally, like many other young biotech companies' stocks, shares of CRISPR Therapeutics (CRSP +0.22%) have fallen in and out of favor since its developmental hopes began turning into reality a few years ago. After a fantastic run-up from 2018 through 2020, this ticker tumbled in 2021 and has since moved sideways. Today's Change ( 0.22 %) $ 0.11 Current Price $ 50.34 There's something that just might light a fire under this stock in the very near future, though. Approved in late 2023, CRISPR Therapeutics' Casgevy, a treatment for sickle cell disease and another blood disorder, was the first-ever gene therapy approved by the Food and Drug Administration for any purpose. And with the help of commercialization partner Vertex Pharmaceuticals, it was ready to hit the ground running shortly thereafter. The only catch? Casgevy is costly and somewhat complicated to administer. While most insurers will eventually cover the treatment's $2.2 million price tag, preapproval verification is obviously required. Each patient's treatment is also custom-created for them starting with a sample of their own blood, a process that can take months to complete, start-to-finish. The business is starting to build since revenue started flowing in earnest in the latter half of last year, however. After last year's total top line of $3.5 million, analysts expect CRISPR Therapeutics' sales to reach on the order of $40 million this year. That's en route to at least twice that amount next year, now that more and more Casgevy patients are in the pipeline and will eventually lead to reportable revenue. Then there's the fact that CRISPR Therapeutics' gene-editing know-how isn't limited to treating sickle cell disease. The biotech has five other promising clinical trials underway, in addition to several more preclinical studies. Those include tests of this science as a treatment for diabetes, as well as for certain kinds of cancer. There's still much work to be done before CRISPR Therapeutics will even be in a position to be profitable, arguably making this company the riskiest of the three in question. However, the potential reward is worth the risk. An outlook from Precedence Research suggests the global CRISPR-based gene-editing therapy market is set to grow from less than $5 billion this year to nearly $15 billion by 2035. That's an annualized growth rate of almost 13%. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-05-19 10:01
2mo ago
|
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know | FMP Stock News | |
|
Original source text
CRISPR Therapeutics AG (CRSP - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this company have returned -15.8%, compared to the Zacks S&P 500 composite's +4% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has lost 7.8%. The key question now is: What could be the stock's future direction? While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making. Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, CRISPR Therapeutics is expected to post a loss of $1.12 per share, indicating a change of +13.2% from the year-ago quarter. The Zacks Consensus Estimate has changed +5.7% over the last 30 days. The consensus earnings estimate of -$5.08 for the current fiscal year indicates a year-over-year change of +21.5%. This estimate has changed -3.2% over the last 30 days. For the next fiscal year, the consensus earnings estimate of $4.37 indicates a change of +14.1% from what CRISPR Therapeutics is expected to report a year ago. Over the past month, the estimate has changed +4%. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, CRISPR Therapeutics is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. In the case of CRISPR Therapeutics, the consensus sales estimate of $8.08 million for the current quarter points to a year-over-year change of +808.1%. The $34.6 million and $129.51 million estimates for the current and next fiscal years indicate changes of +885.6% and +274.4%, respectively. Last Reported Results and Surprise HistoryCRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%. EPS of -$1.28 for the same period compares with -$1.58 a year ago. Compared to the Zacks Consensus Estimate of $8.39 million, the reported revenues represent a surprise of -82.62%. The EPS surprise was -12.28%. Over the last four quarters, CRISPR Therapeutics surpassed consensus EPS estimates two times. The company topped consensus revenue estimates times over this period. ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. CRISPR Therapeutics is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CRISPR Therapeutics. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-05-21 17:40
2mo ago
|
These Are The Upcoming Catalysts For Crispr Therapeutics Stock | FMP Stock News | |
|
Original source text
Crispr Therapeutics AG remains a Buy, supported by a robust pipeline, prudent capital management, and deep Vertex partnership despite slow Casgevy adoption. Casgevy's market penetration is limited by harsh preconditioning, but in vivo approaches and gentler regimens could unlock a vastly larger TAM in coming years. CRSP's diversified pipeline—spanning cardiovascular, diabetes, and CAR-T—offers multiple shots on goal, with key clinical readouts expected throughout 2026. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-05-28 08:00
2mo ago
|
CRISPR Therapeutics to Participate in Upcoming Investor Conferences | FMP Stock News | |
|
Original source text
May 28, 2026 08:00 ET | Source: CRISPR Therapeutics AGZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026 Time: 9:55 a.m. ET William Blair’s 46th Annual Growth Stock Conference Date: Wednesday, June 3, 2026 Time: 4:40 p.m. CT Goldman Sach’s 47th Annual Global Healthcare Conference Date: Tuesday, June 9, 2026 Time: 2:40 p.m. ET A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following the presentation. About CRISPR Therapeutics CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com. Investor Contact: +1-617-307-7503 [email protected] Media Contact: +1-617-315-4493 [email protected] |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-01 10:01
1mo ago
|
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It | FMP Stock News | |
|
Original source text
CRISPR Therapeutics AG (CRSP - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this company have returned +8.8%, compared to the Zacks S&P 500 composite's +6.3% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has gained 2.9%. The key question now is: What could be the stock's future direction? While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making. Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, CRISPR Therapeutics is expected to post a loss of $1.12 per share, indicating a change of +13.2% from the year-ago quarter. The Zacks Consensus Estimate has changed +5.7% over the last 30 days. For the current fiscal year, the consensus earnings estimate of -$4.96 points to a change of +23.3% from the prior year. Over the last 30 days, this estimate has changed -0.6%. For the next fiscal year, the consensus earnings estimate of $4.14 indicates a change of +16.4% from what CRISPR Therapeutics is expected to report a year ago. Over the past month, the estimate has changed -1.4%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for CRISPR Therapeutics. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: 12 Month EPS Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. For CRISPR Therapeutics, the consensus sales estimate for the current quarter of $8.08 million indicates a year-over-year change of +808.1%. For the current and next fiscal years, $34.95 million and $130.93 million estimates indicate +895.6% and +274.7% changes, respectively. Last Reported Results and Surprise HistoryCRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%. EPS of -$1.28 for the same period compares with -$1.58 a year ago. Compared to the Zacks Consensus Estimate of $8.39 million, the reported revenues represent a surprise of -82.62%. The EPS surprise was -12.28%. Over the last four quarters, CRISPR Therapeutics surpassed consensus EPS estimates two times. The company topped consensus revenue estimates times over this period. ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. CRISPR Therapeutics is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CRISPR Therapeutics. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-01 12:30
1mo ago
|
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking | FMP Stock News | |
|
Original source text
Many investors who follow CRISPR Therapeutics (CRSP +0.22%) still treat it as a gene-editing story. That makes sense, as the company's only commercialized drug, Casgevy, is a gene-editing therapy. But this biotech's ambitions are bigger than that modality alone.In May 2025, it paid $95 million up front to Sirius Therapeutics for CTX611, a clinical-stage long-acting small interfering RNA (siRNA) therapy that's being investigated for the prevention of thrombosis and thromboembolic disorders. That often-overlooked program may turn out to be a major asset for the company; here's why. Image source: Getty Images. This program is an asymmetrical bet In a nutshell, CTX611 works by silencing the messenger RNA (mRNA) for the coagulation enzyme Factor XI in the liver. That silencing reduces the production of the coagulation factor, making the patient's blood less likely to form dangerous blood clots. With CTX611, it may be possible to blunt the production of the coagulation factor without causing detrimental side effects like excessive bleeding, which is a problem with traditional anticoagulant medicines like warfarin. CRISPR Therapeutics' candidate is engineered for twice-yearly subcutaneous dosing, which may also be an advantage compared to alternatives that require daily pills or monthly antibody infusions. One important thing to note is that CRISPR Therapeutics made a far smaller up-front commitment than its bigger competitors for a shot at the same market. Novartis paid up to $3.1 billion in 2025 to own abelacimab, a monthly antibody targeting the same coagulation factor. Eliquis, the leading anticoagulant (owned by Pfizer and Bristol Myers Squibb), alone generated $14.4 billion in revenue in 2025. While CRISPR Therapeutics owes Sirius additional milestone payments that could bring the deal's total value to over $800 million, and it'll also bear half of all development costs, that's still a fraction of what Novartis committed. Today's Change ( 0.22 %) $ 0.11 Current Price $ 50.34 There's a catch Competition in the anticoagulant segment is fierce and growing. Aside from biologics being tested by players like Novartis, and improved small-molecule drugs (which build on the successes of the prior generation of those medicines) being tested by other big pharma businesses, CTX611 is not the only siRNA therapy targeting Factor XI. Suzhou Ribo Life Science's candidate, vortosiran, reached the clinic first, and is presently in phase 2b trials. Even if CRISPR Therapeutics manages to get its program approved and out the door first, it'll immediately be competing intensely based on its therapy's cost, convenience, safety, availability, and effectiveness. The takeaway is that CTX611 is most likely to be a follower, rather than a category leader. Nonetheless, given that the biotech only made $1.4 million in revenue in the first quarter of 2026 (though that figure excludes its 40% share of Casgevy revenue due to the way its collaboration is structured), even getting a foothold in the anticoagulants market with this candidate could be immensely impactful for the stock. The biotech expects to deliver an update on the program's progress through its phase 2 clinical trials in the second half of this year, so stay tuned. Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb, CRISPR Therapeutics, and Pfizer. The Motley Fool has a disclosure policy. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-03 03:00
1mo ago
|
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out | FMP Stock News | |
|
Original source text
The weight-loss drug market may be one of the fastest-growing therapeutic areas in the pharmaceutical industry. Eli Lilly (LLY 1.22%) has been a major winner from this boom. The drugmaker's Zepbound is one of the best-selling anti-obesity medicines. Eli Lilly also recently received approval for Foundayo, an oral weight-loss pill that is already seeing decent success. In addition to those approved products, the drugmaker has a pipeline with several other candidates in this area.Eli Lilly could ride the weight loss tailwind for a while, but the company is already looking for the next big thing in the industry. Could Eli Lilly's work in gene editing be it? Let's look at recent clinical trial results for one of Eli Lilly's gene-editing candidates and what they mean for leading companies in this niche, such as CRISPR Therapeutics (CRSP +0.22%). Image source: The Motley Fool. The power of gene editing Gene editing refers to a set of techniques that allow scientists to alter the genetic makeup of organisms. This is a powerful tool at our disposal, as it can help address the root causes of many diseases rather than merely treating their symptoms. The gene editing landscape has made significant progress over the past decade. For instance, in 2023, CRISPR Therapeutics earned approval for the first CRISPR-based therapy. That was a big deal since this technique earned its creators a Nobel Prize in chemistry. In all likelihood, more transformative treatments will be developed through gene editing over the next decade or so. Eli Lilly wants a piece of it. The pharmaceutical giant recently announced clinical trial results for VERVE-102, an investigational gene editing medicine being developed for heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD). Both diseases have a strong genetic component (in fact, the first is a genetic disorder) and lead to elevated levels of LDL cholesterol, which can cause things like heart attacks and strokes. Today's Change ( -1.22 %) $ -14.12 Current Price $ 1146.83 There are ways to manage high LDL levels, notably through diet or exercise, and some prescription medicines can also help. However, for patients at high risk of serious cardiovascular problems, a one-time treatment that can help lower LDL levels permanently might be a game changer. That's exactly what VERVE-102 could be. The results of a phase 1b study Eli Lilly recently announced showed that a one-time infusion of VERVE-102 substantially lowered LDL cholesterol, with the effect appearing durable. A David vs Goliath situation? CRISPR Therapeutics is developing CTX310, a medicine that aims to decrease LDL and triglycerides (TGs, which can also cause cardiovascular issues) in certain patients. CTX310 is also a one-time gene editing medicine. Should CRISPR Therapeutics investors be worried? On the one hand, it's worth noting that although VERVE-102 and CTX310 both aim to reduce cardiovascular risk, they target different patient populations (CTX310 is going after patients with HeFH or several other conditions) and have distinct mechanisms of action. Today's Change ( 0.22 %) $ 0.11 Current Price $ 50.34 Also, as CRISPR Therapeutics points out, there are 40 million patients with elevated LDL or TGs (or both) in the U.S. alone, so this is a vast market that could accommodate multiple winners. However, Eli Lilly may be just getting started making some noise in the gene editing space. And if it continues to do so -- and is successful -- the pharmaceutical leader might end up being a significant threat to smaller gene editing players like CRISPR Therapeutics. Investors need to keep that in mind. Which stock should you buy? Provided gene editing represents the next gold rush in the industry, Eli Lilly and CRISPR Therapeutics offer very different value propositions. The former is a well-established drugmaker with significant footprints across several therapeutic areas and a lead in the diabetes and weight-loss markets. Eli Lilly generates consistent revenue and profits, has a deep pipeline, and a respectable dividend program. Its work on gene editing is a relatively small aspect of the business, so for investors looking for exposure to this niche, Eli Lilly is a fairly safe option. CRISPR Therapeutics, on the other hand, focuses almost entirely on gene editing. The stock could soar as it makes significant clinical progress over the next few years, but setbacks might also sink CRISPR Therapeutics' share price. In other words, CRISPR Therapeutics is the more aggressive option; it arguably offers higher upside, but the trade-off is an elevated risk profile. Only investors comfortable with volatility should consider initiating a position in CRISPR Therapeutics. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-03 12:30
1mo ago
|
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential | FMP Stock News | |
|
Original source text
For years, CRISPR Therapeutics (CRSP +0.22%) has been the type of stock investors might call a home run swing. The company develops medicines using gene-editing technologies to treat or cure serious conditions and diseases that traditional pharmaceutical drugs cannot.The stock has generated good returns over time, but it's been a very bumpy ride at times. Today, CRISPR Therapeutics' stock trades at a fraction of its former price. However, Wall Street analysts see opportunity. On CNN Business, 58% of Wall Street analysts have rated CRISPR Therapeutics as a buy, with price targets signaling as much as 437% upside. Here's a look at why analysts might be bullish. Image source: The Motley Fool. Commercial revenue is finally taking off CRISPR Therapeutics has been around for years, but it only recently commercialized its first product. Casgevy is a gene editing treatment co-developed with Vertex Pharmaceuticals to treat sickle cell disease and transfusion-dependent beta thalassemia. It's a one-time treatment tailored to each patient's edited DNA that functionally mutes the disease, coming as close to a functional cure as you can get. It takes time to treat patients with Casgevy; patients submit a sample of their DNA, which is edited and then reintroduced into the patient. CRISPR and Vertex received FDA approval in late 2023. Yet only 64 patients received Casgevy infusions in 2025. The company generated $4.1 million in sales last year. Analysts see revenue growing to $43.9 million this fiscal year and to $151.6 million next fiscal year. One-time treatments don't generate recurring revenue, but there's a vast patient pool. CRISPR estimates 60,000 eligible patients are in the United States and other countries where the therapy is approved. Today's Change ( 0.22 %) $ 0.11 Current Price $ 50.34 CRISPR stock is absurdly cheap -- if you look at the big picture The stock doesn't look cheap at first glance. At its current market cap of $5.4 billion, CRISPR still trades at roughly 35 times next year's revenue estimates. But things change as you zoom out. CRISPR has a strong pipeline, with five other therapies at various stages of clinical trials. If even one or two of those hit, it's a potential game changer. CRISPR wholly owns four of those five therapies, meaning significantly more financial upside if they make it through trials and to the market. In the meantime, Casgevy will continue to grow and create a financial floor for the company. Some of the world's largest pharmaceutical companies are worth hundreds of billions of dollars. CRISPR Therapeutics has a long way to go, but the ceiling is quite high. Gene editing produced a revolutionary treatment in Casgevy, and it can duplicate that success in some of the harshest known diseases, where traditional pharmaceuticals have failed. This is all still highly speculative, so investors should tread carefully. That said, CRISPR's relatively modest market cap and its first big win with Casgevy make the stock a potential home run over the next decade, worth buying and holding to take that swing. If things go well, that 437% upside from analysts doesn't look so outlandish at all. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-03 12:30
1mo ago
|
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report? | FMP Stock News | |
|
Original source text
A month has gone by since the last earnings report for CRISPR Therapeutics AG (CRSP - Free Report) . Shares have lost about 0.7% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is CRISPR Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers. Wider-Than-Expected Loss in Q1, Sales Miss EstimatesCRISPR reported a first-quarter 2026 loss of $1.28 per share, wider than the Zacks Consensus Estimate of a loss of $1.14. The company had incurred a loss of $1.58 in the year-ago quarter. Total revenues were $1.46 million in the quarter (comprising $1 million in collaboration revenue and the rest from grant revenues), which significantly missed the Zacks Consensus Estimate of $8.39 million. In the year-ago period, CRSP recorded total revenues of $0.87 million, which comprised only grant revenues. Vertex recorded Casgevy sales of about $43 million in the quarter, up from $14.2 million in the year-ago period. This revenue growth was attributed to continued uptake for therapy and reimbursement progress across major regions. Manages Costs While Strengthening Balance SheetCRISPR Therapeutics reported research and development (R&D) expenses of $68.6 million in the first quarter of 2026, down 5.4% year over year. The company attributed the decline primarily to lower employee-related costs, including stock-based compensation, reflecting continued efforts to align spending with program priorities. General and administrative expenses were $17.2 million, down about 11% year over year, mainly due to lower employee-related costs. Collaboration expense, net, improved to $45.9 million from $57.5 million, due to an increase in the company’s share of Casgevy sales under the Vertex collaboration economics. CRSP exited the quarter with $2.44 billion in cash, cash equivalents and marketable securities, up from $1.98 billion at the end of 2025. It said the increase was primarily driven by $585.4 million in net proceeds from the issuance of convertible senior notes in March, partially offset by operating expenses. The higher cash position strengthens the company’s ability to fund operations as it works to broaden its revenue base over time. Balance sheet metrics also reflected the larger liquidity position, with working capital rising to $2.31 billion and total assets increasing to $2.73 billion as of March 31, 2026. For investors, the higher cash base provides additional flexibility to fund multiple clinical updates expected later in 2026 across Casgevy expansion efforts, zugo-cel studies and liver-directed in vivo programs. How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted 5.67% due to these changes. VGM ScoresCurrently, CRISPR Therapeutics has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. However, the stock has a score of F on the value side, putting it in the lowest quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Notably, CRISPR Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-03 21:32
1mo ago
|
CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript | FMP Stock News | |
|
Original source text
CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-04 19:32
1mo ago
|
CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript | FMP Stock News | |
|
Original source text
CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-08 12:53
1mo ago
|
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? | FMP Stock News | |
|
Original source text
By all accounts, CRISPR Therapeutics (CRSP +0.22%) shares should be soaring. The company shares rights to one of the healthcare industry's very few approved gene-editing therapies, and has several more in the works.Initial interest in its sole approved treatment is solid, too. Despite a steep price tag of $2.2 million per patient, over 500 people have at least begun using its single marketed therapy, one that was only approved in late 2023. And the debt-light $5.5 billion company has over $2.4 billion worth of liquidity, while analysts' consensus price target of $80.62 is 40% above the stock's current price. Yet shares of the biopharma are seemingly stuck, unable to make any progress since 2022, even though its story has become so much more compelling during this time frame. What gives? Nothing that's really all that surprising, all things considered. And the stock's stagnation isn't a reason not to take a swing on it sooner rather than later. But first things first. What exactly does this company do? Today's Change ( 0.22 %) $ 0.11 Current Price $ 50.34 CRISPR Therapeutics is obviously a biopharma name -- but it's a unique one. Co-founder Emmanuelle Charpentier and her research collaborator Jennifer Doudna co-invented the CRISPR/Cas9 gene-editing technique. It not only became the scientific basis for the company's drugs, but also won the pair a Nobel Prize in Chemistry in 2020. But what is "CRISPR?" It's an acronym for "clustered regularly interspaced short palindromic repeats" -- a pattern observed within the antiviral DNA of small organisms like bacteria. Cas9 is an enzyme that splices a DNA chain in a very specific spot identified by guide RNA, allowing a damaged or faulty sequence to be replaced with a corrected sequence created by CRISPR technology. Its potential uses are considerable, although CRISPR Therapeutics got the ball rolling with a relatively modest one. Its gene-editing therapy Casgevy, approved in 2023, is aimed at the inherited blood disorders sickle cell disease and beta thalassemia. Bigger and better targets are in the works, though. The company's clinical pipeline includes trials of the same gene-editing approach to treat cardiovascular disease and diabetes, while ailments like cystic fibrosis, muscular dystrophy, and hypertension are longer-term prospects currently in preclinical studies. Why investors are remaining on the sidelines Sounds good. So why isn't the stock moving? There are a handful of factors working against it here. One of them is the price tag of the treatment: At $2.2 million a pop, insurers are obviously requiring a considerable amount of justification. Another stumbling block is the sheer complexity of the treatment process, which is slowing revenue reporting. Casgevy isn't a simple injection that's mass-manufactured; it's customized for each patient using a sample of their own blood stem cells, and can take months from start to finish. CRISPR Therapeutics doesn't get to book any patient revenue until the end of the treatment process. Image source: Getty Images. Investors may also be disappointed in what seem like agonizingly poor results and sizable losses right now and for the foreseeable future. Although next year's projected revenue of $151.7 million is a marked improvement over this year's likely top line of $44 million, that's still weak for a $5.5 billion company that developed a breakthrough treatment, with more game-changing drugs in the works. Another factor is Vertex Pharmaceuticals (VRTX 0.50%), its partner in the Casgevy business. (Vertex has 60% of the partnership, compared to its own 40%.) CRISPR Therapeutics needs Vertex's sample-collection and treatment centers. The two companies are splitting profits and losses on the drug, though, and like most young drugs, this one remains unprofitable to start. Although Vertex has other revenue-bearing and profitable products in its portfolio, CRISPR Therapeutics doesn't -- at least, not yet. Then there's the recent fundraiser, which may not be the last one for a while. In March, CRISPR Therapeutics issued $600 million in notes that could be converted into over 7.8 million shares of stock, potentially diluting the 96.5 million shares currently outstanding. This paper essentially acts like debt in the meantime, requiring the company to make semi-annual interest payments. This is the norm for up-and-coming biopharma companies That's a lot of stumbling blocks -- paired with a pipeline that's promising, but far from guaranteed to produce a bunch of approved drugs in the near or distant future. It's not difficult to see why interested investors are balking. The thing is, there's nothing particularly unusual about any of this for an up-and-coming biopharma name. They all tend to suffer losses early on, so they all need to regularly raise new capital. No start-up pharma outfit can guarantee that every clinical trial will turn into an approved, marketable drug. Neither can the biggest names in the pharmaceutical business. So there's risk here, to be sure, but it's commensurate with the potential reward. Mordor Intelligence expects the nascent gene-editing therapy market to grow at an average annual pace of 16% through 2031, when it will be worth nearly $26 billion per year (although this outlook arguably still understates the potential of gene-editing treatments). The bottom line? If you can stomach the above-average risk and stick with it for a while, there's meaningful upside here. As a 12-month target, the consensus analyst price target of $80.62 is just the beginning. While the company and the stock make forward progress, look for this bullishness to grow. The tough part is just waiting for something -- or someone -- to get the ball rolling in the meantime. It seems like most investors are waiting on the sidelines for a clear catalyst. Of course, all too often, waiting for such a catalyst means you'll miss out on some sizable early gains. With all that said, given the strength of its intellectual property and pipeline, there's also an argument to be made that CRISPR Therapeutics is a candidate for acquisition by a bigger player, one with deeper developmental pockets and more marketing firepower. But that's still not enough reason to step into this stock. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-09 17:02
1mo ago
|
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript | FMP Stock News | |
|
Original source text
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-10 19:01
1mo ago
|
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know | FMP Stock News | |
|
Original source text
In the latest close session, CRISPR Therapeutics AG (CRSP - Free Report) was down 3.9% at $49.47. The stock's change was less than the S&P 500's daily loss of 1.62%. Elsewhere, the Dow saw a downswing of 1.87%, while the tech-heavy Nasdaq depreciated by 1.98%.The company's stock has dropped by 2.56% in the past month, falling short of the Medical sector's gain of 5.04% and the S&P 500's loss of 0.03%. The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.11 per share, which would represent year-over-year growth of 13.95%. At the same time, our most recent consensus estimate is projecting a revenue of $9.28 million, reflecting a 942.7% rise from the equivalent quarter last year. For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.92 per share and revenue of $38.88 million, which would represent changes of +23.96% and +1007.58%, respectively, from the prior year. Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 3.42% rise in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG presently features a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-11 16:14
1mo ago
|
VO: Mid Caps Now Look Attractive, But Vanguard's $103 Billion ETF Misses The Mark | FMP Stock News | |
|
Original source text
VO is a low-cost ETF offered by Vanguard, providing broad exposure to U.S. mid-cap stocks as defined by CRSP. However, CRSP Indexes allow overlap with the small/large-cap segments, impacting efficiency. As is common for Vanguard ETFs, VO will most likely deliver average category returns year to year, as it has done historically. However, it's not ideal from a fundamentals perspective. This article suggests combining XMHQ and XMMO to create a high-quality portfolio with strong momentum characteristics, potentially allowing for lesser drawdowns and faster recoveries. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-06-11 18:51
1mo ago
|
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts | FMP Stock News | |
|
Original source text
CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $50.27, demonstrating a +1.68% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 1.75%. Elsewhere, the Dow saw an upswing of 1.86%, while the tech-heavy Nasdaq appreciated by 2.54%.Heading into today, shares of the company had lost 6.27% over the past month, lagging the Medical sector's gain of 3.73% and the S&P 500's loss of 1.63%. The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. The company is expected to report EPS of -$1.11, up 13.95% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $9.28 million, indicating a 942.7% growth compared to the corresponding quarter of the prior year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$4.9 per share and revenue of $38.88 million, indicating changes of +24.27% and +1007.58%, respectively, compared to the previous year. It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.99% higher within the past month. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 153, positioning it in the bottom 38% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-03-13 02:50
4mo ago
|
Holcim (OTCMKTS:HCMLY) and Frontdoor (NASDAQ:FTDR) Head to Head Contrast | FMP Stock News | |
|
Original source text
Holcim (OTCMKTS:HCMLY - Get Free Report) and Frontdoor (NASDAQ: FTDR - Get Free Report) are both construction companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Profitability This table compares Holcim and Frontdoor's net margins, return |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-03-15 01:58
4mo ago
|
Frontdoor (NASDAQ:FTDR) vs. Compagnie de Saint-Gobain (OTCMKTS:CODYY) Head-To-Head Contrast | FMP Stock News | |
|
Original source text
Frontdoor (NASDAQ: FTDR - Get Free Report) and Compagnie de Saint-Gobain (OTCMKTS:CODYY - Get Free Report) are both construction companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Risk and Volatility Frontdoor has a beta of |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-03-15 03:27
4mo ago
|
Algert Global LLC Acquires 51,214 Shares of Frontdoor Inc. $FTDR | FMP Stock News | |
|
Original source text
Algert Global LLC increased its holdings in shares of Frontdoor Inc. (NASDAQ: FTDR) by 24.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 260,233 shares of the company's stock after purchasing an additional 51,214 shares during the |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-03-17 07:45
4mo ago
|
Dennis Howard Joins Frontdoor Board of Directors | FMP Stock News | |
|
Original source text
-Global executive brings wealth of knowledge and expertise in information technology, cybersecurity, operations and innovation MEMPHIS, Tenn.--(BUSINESS WIRE)--Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home warranties and new home builder warranties, today announced that its board unanimously approved the election of Dennis Howard as a director and appointed him as a member of the Audit Committee, effective today. “We are thrilled to welcome Dennis to Frontdoor’s board,” said Bill Cobb, Frontdoor’s Chairman and Chief Executive Officer. “Dennis brings over 30 years of experience in information technology and cybersecurity across several consumer-focused businesses. He possesses a deep understanding of digital platforms, enterprise systems and data analytics trends – which will greatly help us as we continue to optimize and improve our use of technology in the future. Further, his keen innovative and operational mindset will be a strong asset to our board.” Howard currently serves as the Managing Director, Chief Technology, Operations, and Data Officer for Charles Schwab, a global financial services firm. He is responsible for Charles Schwab’s information technology, including a centralized technology organization and an enterprise project management office. In addition, Howard is responsible for the firm’s data assets, teams that handle all operational transactions for current clients of Charles Schwab, and transformation-related initiatives. He joined Charles Schwab in September 2014 as Senior Vice President of core technology solutions and served as the firm’s Executive Vice President and Chief Information Officer from 2016-2025. “I am very excited to join the Frontdoor board,” Howard said. “I look forward to working closely with my fellow directors and the company’s leadership team to help take Frontdoor to the next level in this rapidly changing digital environment. Frontdoor already has a strong operational and technology foundation, and I’m excited to be able to contribute to Frontdoor’s continued and future business success.” Prior to Charles Schwab, Howard was Senior Vice President and Chief Information Officer for Visa Inc. During his 12-year tenure at Visa, he served in various information technology roles across a number of disciplines, including development of enterprise systems, data and analytics, and client-facing product development. Howard received his bachelor's degree from the University of Texas at San Antonio, and his master's degree from Baylor University. Howard will stand for re-election at the company’s 2026 annual meeting of stockholders. About Frontdoor Frontdoor and its family of brands are on a mission to make life easier for every homeowner through innovative technology and quality customer service. With over 55 years of experience, we are the leading provider of home warranties in the United States, handling approximately 3.8 million service requests for more than 2.1 million members through a network of approximately 17,000 qualified and independent service contractors. We also offer new home builder warranty solutions, which deliver value to both builders and homeowners through a suite of builder warranty products and support services. Our customizable home warranties are annual service plan agreements that cover the repair or replacement for breakdowns due to normal wear and tear of major components. We cover up to 29 home systems and appliances, including electrical, plumbing, HVAC systems, water heaters, refrigerators, dishwashers and ranges/ovens/cooktops, as well as optional coverages for pools, spas and pumps. Our home warranties provide peace of mind, budget protection, convenience, repair expertise and service guarantee. Our non-warranty services provide homeowners greater value through replacement and upgrade programs, as well as other home maintenance offerings. Our 2-10 new home builder warranty solutions offer flexible builder‑backed and insurance‑backed warranty options covering workmanship, home distribution systems and structural components. Frontdoor family of brands include American Home Shield, HSA, OneGuard, Landmark and 2-10 HBW brands. For more information about Frontdoor, Inc., please visit frontdoorhome.com. Forward Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements, because actual results may vary materially from those expressed or implied. The reports filed by Frontdoor pursuant to United States securities laws contain discussions of these risks and uncertainties. Frontdoor assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review Frontdoor's filings with the United States Securities and Exchange Commission (which are available on the SEC's EDGAR database at www.sec.gov and via Frontdoor’s website at investors.frontdoorhome.com). FTDR-Company More News From Frontdoor, Inc. Back to Newsroom |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-03-19 11:55
4mo ago
|
Frontdoor Stock Pullback: A Buying Opportunity Or A Value Trap? | FMP Stock News | |
|
Original source text
Frontdoor (FTDR) stock has dropped by 12.7% in under a month, declining from $69.11 on March 3rd, 2026 to $60.30 at present. Should you consider buying this dip? |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-03-25 02:37
4mo ago
|
Critical Survey: Frontdoor (NASDAQ:FTDR) vs. Owens Corning (NYSE:OC) | FMP Stock News | |
|
Original source text
Owens Corning (NYSE: OC - Get Free Report) and Frontdoor (NASDAQ: FTDR - Get Free Report) are both mid-cap construction companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations. Profitability This table compares Owens Corning and Frontdoor's |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-03-30 03:15
3mo ago
|
Assenagon Asset Management S.A. Raises Stake in Frontdoor Inc. $FTDR | FMP Stock News | |
|
Original source text
Posted by Defense World Staff on Mar 30th, 2026Assenagon Asset Management S.A. lifted its stake in shares of Frontdoor Inc. (NASDAQ:FTDR – Free Report) by 112.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 80,069 shares of the company’s stock after purchasing an additional 42,462 shares during the quarter. Assenagon Asset Management S.A. owned about 0.11% of Frontdoor worth $4,619,000 at the end of the most recent quarter. Other large investors have also made changes to their positions in the company. Invesco Ltd. boosted its holdings in Frontdoor by 2.5% during the third quarter. Invesco Ltd. now owns 1,108,815 shares of the company’s stock worth $74,612,000 after buying an additional 27,410 shares in the last quarter. Wasatch Advisors LP increased its holdings in Frontdoor by 2.7% in the third quarter. Wasatch Advisors LP now owns 968,286 shares of the company’s stock valued at $65,156,000 after buying an additional 25,613 shares in the last quarter. Broad Bay Capital Management LP acquired a new stake in shares of Frontdoor during the 2nd quarter valued at approximately $46,886,000. Bank of America Corp DE lifted its position in shares of Frontdoor by 4.7% during the 2nd quarter. Bank of America Corp DE now owns 699,289 shares of the company’s stock valued at $41,216,000 after acquiring an additional 31,087 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH boosted its stake in shares of Frontdoor by 18.4% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 627,791 shares of the company’s stock worth $42,244,000 after acquiring an additional 97,565 shares in the last quarter. Analyst Ratings Changes A number of equities research analysts recently weighed in on FTDR shares. Weiss Ratings upgraded Frontdoor from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, March 23rd. Oppenheimer reiterated an “outperform” rating and set a $70.00 target price on shares of Frontdoor in a research report on Thursday, February 26th. Wall Street Zen lowered Frontdoor from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. The Goldman Sachs Group upgraded Frontdoor from a “sell” rating to a “neutral” rating and raised their price target for the company from $50.00 to $67.00 in a research report on Monday, March 2nd. Finally, Truist Financial set a $71.00 price target on Frontdoor in a research note on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.60. View Our Latest Report on Frontdoor Frontdoor Price Performance FTDR stock opened at $53.64 on Monday. The stock’s 50 day moving average price is $59.93 and its 200 day moving average price is $60.00. The firm has a market cap of $3.79 billion, a P/E ratio of 15.73 and a beta of 1.31. The company has a debt-to-equity ratio of 4.73, a quick ratio of 1.55 and a current ratio of 1.55. Frontdoor Inc. has a 1 year low of $35.61 and a 1 year high of $70.77. Frontdoor (NASDAQ:FTDR – Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.12. Frontdoor had a return on equity of 120.79% and a net margin of 12.18%.The company had revenue of $433.00 million during the quarter, compared to the consensus estimate of $421.62 million. During the same quarter last year, the business posted $0.27 earnings per share. Frontdoor’s revenue was up 13.1% compared to the same quarter last year. On average, sell-side analysts expect that Frontdoor Inc. will post 3.07 earnings per share for the current fiscal year. Frontdoor Profile (Free Report) Frontdoor, Inc (NASDAQ:FTDR) is a leading provider of home service plans and repair solutions for residential property owners. The company offers contract-based coverage that helps homeowners manage the cost of repairing and replacing essential household systems and appliances, including heating and cooling, plumbing, electrical wiring, water heaters, washers, dryers, refrigerators and other major kitchen equipment. Frontdoor delivers its services through a nationwide network of independent service professionals and contractors, leveraging a cloud-based platform and call center infrastructure to coordinate service visits and process claims. See Also Five stocks we like better than Frontdoor Receive News & Ratings for Frontdoor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frontdoor and related companies with MarketBeat.com's FREE daily email newsletter. « PREVIOUS HEADLINEBroadcom Inc. $AVGO Stake Boosted by Argentarii LLC NEXT HEADLINE »Grand Canyon Education, Inc. $LOPE Shares Sold by Assenagon Asset Management S.A. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-03-31 17:05
3mo ago
|
American Home Shield and Rachel Dratch Return for Year Three of “Warrantina” to Demystify the Misconceptions of Home Warranties | FMP Stock News | |
|
Original source text
-The “Don’t Worry. Be Warranty.” campaign evolves from brand awareness to category education, using the iconic “Warrantina” to simplify homeownership. MEMPHIS, Tenn.--(BUSINESS WIRE)--Frontdoor, Inc. (NASDAQ: FTDR), the parent company of American Home Shield, the nation’s leading provider of home warranties, today announced the third year of its “Don’t Worry. Be Warranty.” marketing campaign. The latest iteration reunites American Home Shield with Emmy®-nominated comedienne Rachel Dratch – bringing back her well-known “Warrantina” character to further educate homeowners and demystify the home warranty category. Entering its third year, the campaign is moving beyond broad awareness into a deeper phase of homeowner education. By featuring Warrantina across various comedic tropes—from mystical fortune tellers to community theater—the series, directed by Benji Weinstein, aims to dismantle the misconceptions of home protection for a new generation of homeowners. “A lot of people don’t realize owning a home is basically just waiting for one mysterious, expensive breakdown after another,” said Rachel Dratch. “In our new round of scenes, Warrantina has moved beyond ‘what’s a home warranty?’ to ‘here’s how it actually works.’ We’re using these new scenarios to dispel that sense of worry in the simplest terms, and I’m just happy to be back making sure people don't panic when their water heater decides to retire.” While iterations of the campaign introduced the "Warrantina" character, this year’s campaign puts the American Home Shield service experience center stage to demonstrate its value in real time. A key focus of this year's storytelling is the “No Matter How Old” assurance—a direct response to the concerns of first-time buyers moving into older homes with inherited appliances. “By bringing back Warrantina and our partnership with Rachel Dratch for a third year, we’re shifting the conversation from brand recognition to brand utility,” said Kathy Collins, senior vice president and chief revenue officer for Frontdoor, Inc. “This evolution is about proving the value of a home warranty through transparency and tech-enabled solutions that reflect the actual lives of today’s diverse homeowners. We’re not just telling them we have their back; we’re showing them exactly how we do it.” In a creative shift, one centerpiece spot within the campaign leans into Dratch’s sketch-comedy roots to break the fourth wall. The brand flips the traditional informercial format on its head to visualize the seamless connection to home solutions that the AHS experience provides. “For Year three, we wanted to subvert the typical 'how-to' and lean into the beautiful chaos of homeownership,” said Leslie Shaffer, chief creative officer at Fallon. “Reuniting Rachel and Director Benji Weinstein allowed us to explore different home stories, including a more ‘meta’ style of comedy—breaking the fourth wall to show exactly how the service works with a wink and a healthy dose of whimsy.” The “Don’t Worry. Be Warranty.” Year three campaign is currently airing across national broadcast, streaming and digital channels. For more information, visit ahs.com. About Frontdoor Frontdoor and its family of brands are on a mission to make life easier for every homeowner through innovative technology and quality customer service. With over 55 years of experience, we are the leading provider of home warranties in the United States, handling approximately 3.8 million service requests for more than 2.1 million members through a network of approximately 17,000 qualified and independent service contractors. We also offer new home builder warranty solutions, which deliver value to both builders and homeowners through a suite of builder warranty products and support services. Our customizable home warranties are annual service plan agreements that cover the repair or replacement for breakdowns due to normal wear and tear of major components. We cover up to 29 home systems and appliances, including electrical, plumbing, HVAC systems, water heaters, refrigerators, dishwashers and ranges/ovens/cooktops, as well as optional coverages for pools, spas and pumps. Our home warranties provide peace of mind, budget protection, convenience, repair expertise and service guarantee. Our non-warranty services provide homeowners greater value through replacement and upgrade programs, as well as other home maintenance offerings. Our 2-10 new home builder warranty solutions offer flexible builder‑backed and insurance‑backed warranty options covering workmanship, home distribution systems and structural components. Frontdoor family of brands include American Home Shield, HSA, OneGuard, Landmark and 2-10 HBW brands. For more information about Frontdoor, Inc., please visit frontdoorhome.com. FTDR-Company More News From American Home Shield Back to Newsroom |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-04-08 04:46
3mo ago
|
SG Americas Securities LLC Raises Holdings in Frontdoor Inc. $FTDR | FMP Stock News | |
|
Original source text
Posted by Defense World Staff on Apr 8th, 2026SG Americas Securities LLC grew its position in shares of Frontdoor Inc. (NASDAQ:FTDR – Free Report) by 553.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,287 shares of the company’s stock after purchasing an additional 18,031 shares during the period. SG Americas Securities LLC’s holdings in Frontdoor were worth $1,228,000 at the end of the most recent reporting period. Other institutional investors have also recently made changes to their positions in the company. Broad Bay Capital Management LP purchased a new position in shares of Frontdoor during the second quarter valued at approximately $46,886,000. Eventide Asset Management LLC purchased a new position in shares of Frontdoor during the second quarter valued at approximately $28,506,000. Marshall Wace LLP purchased a new position in shares of Frontdoor during the third quarter valued at approximately $23,871,000. Cubist Systematic Strategies LLC boosted its position in shares of Frontdoor by 309.6% during the second quarter. Cubist Systematic Strategies LLC now owns 431,446 shares of the company’s stock valued at $25,429,000 after buying an additional 326,112 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Frontdoor by 533.0% during the first quarter. Millennium Management LLC now owns 307,497 shares of the company’s stock valued at $11,814,000 after purchasing an additional 258,920 shares during the period. Wall Street Analyst Weigh In FTDR has been the subject of a number of recent analyst reports. The Goldman Sachs Group raised shares of Frontdoor from a “sell” rating to a “neutral” rating and boosted their target price for the company from $50.00 to $67.00 in a research note on Monday, March 2nd. Wall Street Zen lowered shares of Frontdoor from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Truist Financial set a $71.00 target price on shares of Frontdoor in a research note on Monday, January 26th. Benchmark began coverage on shares of Frontdoor in a research note on Thursday, March 26th. They set a “buy” rating and a $80.00 target price for the company. Finally, Oppenheimer reiterated an “outperform” rating and issued a $70.00 price target on shares of Frontdoor in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.60. Read Our Latest Stock Analysis on Frontdoor Frontdoor Stock Down 1.4% Frontdoor stock opened at $54.99 on Wednesday. The business has a fifty day moving average of $59.22 and a two-hundred day moving average of $59.40. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of 4.73. The firm has a market cap of $3.88 billion, a P/E ratio of 16.13 and a beta of 1.41. Frontdoor Inc. has a twelve month low of $36.79 and a twelve month high of $70.77. Frontdoor (NASDAQ:FTDR – Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.12. The company had revenue of $433.00 million during the quarter, compared to analyst estimates of $421.62 million. Frontdoor had a return on equity of 120.79% and a net margin of 12.18%.Frontdoor’s revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.27 earnings per share. On average, analysts forecast that Frontdoor Inc. will post 3.07 earnings per share for the current fiscal year. Frontdoor Company Profile (Free Report) Frontdoor, Inc (NASDAQ:FTDR) is a leading provider of home service plans and repair solutions for residential property owners. The company offers contract-based coverage that helps homeowners manage the cost of repairing and replacing essential household systems and appliances, including heating and cooling, plumbing, electrical wiring, water heaters, washers, dryers, refrigerators and other major kitchen equipment. Frontdoor delivers its services through a nationwide network of independent service professionals and contractors, leveraging a cloud-based platform and call center infrastructure to coordinate service visits and process claims. Featured Stories Five stocks we like better than Frontdoor Want to see what other hedge funds are holding FTDR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Frontdoor Inc. (NASDAQ:FTDR – Free Report). Receive News & Ratings for Frontdoor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frontdoor and related companies with MarketBeat.com's FREE daily email newsletter. « PREVIOUS HEADLINESG Americas Securities LLC Buys 34,303 Shares of Forward Air Corporation $FWRD NEXT HEADLINE »SG Americas Securities LLC Raises Stake in Taylor Morrison Home Corporation $TMHC |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-04-09 08:30
3mo ago
|
Frontdoor, Inc. to Announce First Quarter 2026 Results | FMP Stock News | |
|
Original source text
-MEMPHIS, Tenn.--(BUSINESS WIRE)--Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home warranties, today announced it will release its first quarter financial results and hold a conference call on Thursday, April 30, 2026 at 7:30 a.m. Central time (8:30 a.m. Eastern time). Participants can register for the webcast by clicking https://www.webcaster5.com/Webcast/Page/3067/53785, which will include a slide presentation highlighting the company’s results. Once completed, each participant will receive access details via email. Participants may join via conference call by dialing 888.506.0062 (or international participants, 973.528.0011) and entering conference ID 109396. To participate via webcast and view the presentation, visit https://investors.frontdoorhome.com/. The call will be available for replay for approximately 60 days. To access the replay of this call, please call 877.481.4010 and enter conference passcode 53785 (international participants: 919.882.2331, conference passcode 53785). To view a replay of the webcast, visit https://investors.frontdoorhome.com/. About Frontdoor Frontdoor and its family of brands are on a mission to make life easier for every homeowner through innovative technology and quality customer service. With over 55 years of experience, we are the leading provider of home warranties in the United States, handling approximately 3.8 million service requests for more than 2.1 million members through a network of approximately 17,000 qualified and independent service contractors. We also offer new home builder warranty solutions, which deliver value to both builders and homeowners through a suite of builder warranty products and support services. Our customizable home warranties are annual service plan agreements that cover the repair or replacement for breakdowns due to normal wear and tear of major components. We cover up to 29 home systems and appliances, including electrical, plumbing, HVAC systems, water heaters, refrigerators, dishwashers and ranges/ovens/cooktops, as well as optional coverages for pools, spas and pumps. Our home warranties provide peace of mind, budget protection, convenience, repair expertise and service guarantee. Our non-warranty services provide homeowners greater value through replacement and upgrade programs, as well as other home maintenance offerings. Our 2-10 new home builder warranty solutions offer flexible builder‑backed and insurance‑backed warranty options covering workmanship, home distribution systems and structural components. Frontdoor family of brands include American Home Shield, HSA, OneGuard, Landmark and 2-10 HBW brands. For more information about Frontdoor, Inc., please visit frontdoorhome.com. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by Frontdoor pursuant to United States securities laws contain discussions of these risks and uncertainties. Frontdoor assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review Frontdoor's filings with the United States Securities and Exchange Commission, which are available on the SEC's EDGAR database at www.sec.gov and via Frontdoor’s website at investors.frontdoorhome.com. FTDR-Financial More News From Frontdoor, Inc. Back to Newsroom |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-04-15 09:05
3mo ago
|
American Home Shield Expands Technology Partnership with SkySlope | FMP Stock News | |
|
Original source text
-Simplified process, fewer forms help streamline real estate transactions MEMPHIS, Tenn.--(BUSINESS WIRE)--Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home warranties, today announced an expanded relationship with technology provider SkySlope to help simplify transactions for real estate agents and brokers in 43 states. SkySlope’s solution streamlines the home warranty application process by eliminating unnecessary forms and automating the entire process into a single, centralized workflow. As a result, real estate agents can move faster and focus more on serving clients instead of spending time filling out multiple or duplicate documents. After 6 years of success with SkySlope in 4 states, American Home Shield is expanding the relationship to support nearly 175,000 brokers and agents in 43 states. “Our company purpose is to make life easier for every homeowner, and this partnership with SkySlope gives us another set of tools to help simplify the work of real estate agents and brokers,” said Kathy Collins, Frontdoor chief revenue officer. “We’re creating more value by streamlining their real estate transactions, reducing manual entry and giving them back more time to support homebuyers in other aspects of the complex home purchasing process.” “We’re delighted to grow our partnership with American Home Shield,” said SkySlope CEO Tyler Smith. “At SkySlope, everything we build is focused on helping agents move faster, stay organized, and deliver a better experience for their clients. By simplifying home warranty workflows inside the transaction, we’re giving agents back valuable time to focus on what matters most—closing deals and serving people.” About Frontdoor Frontdoor and its family of brands are on a mission to make life easier for every homeowner through innovative technology and quality customer service. With over 55 years of experience, we are the leading provider of home warranties in the United States, handling approximately 3.8 million service requests for more than 2.1 million members through a network of approximately 17,000 qualified and independent service contractors. We also offer new home builder warranty solutions, which deliver value to both builders and homeowners through a suite of builder warranty products and support services. Our customizable home warranties are annual service plan agreements that cover the repair or replacement for breakdowns due to normal wear and tear of major components. We cover up to 29 home systems and appliances, including electrical, plumbing, HVAC systems, water heaters, refrigerators, dishwashers and ranges/ovens/cooktops, as well as optional coverages for pools, spas and pumps. Our home warranties provide peace of mind, budget protection, convenience, repair expertise and service guarantee. Our non-warranty services provide homeowners greater value through replacement and upgrade programs, as well as other home maintenance offerings. Our 2-10 new home builder warranty solutions offer flexible builder‑backed and insurance‑backed warranty options covering workmanship, home distribution systems and structural components. Frontdoor family of brands include American Home Shield, HSA, OneGuard, Landmark and 2-10 HBW brands. For more information about Frontdoor, Inc., please visit frontdoorhome.com. About SkySlope Since 2011, SkySlope has led real estate innovation, working closely with brokers to deliver intelligent solutions that drive transformation. As one of the industry’s original disruptors, it has become the trusted platform for managing transactions from contract to close, empowering 900,000 real estate professionals across the U.S. and Canada. With nearly three million transactions handled annually, SkySlope is dedicated to collaborating with agents and brokers to redefine how they work, building a legacy that propels the real estate industry forward. For more information, visit SkySlope.com. FTDR-Company More News From Frontdoor, Inc. Back to Newsroom |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-04-15 17:23
3mo ago
|
Frontdoor: The Hidden Growth The Market Is Ignoring | FMP Stock News | |
|
Original source text
Frontdoor, Inc., a leading home service warranty provider, suffered post-Covid as its real estate channel faced serious headwinds. But FTDR pivoted to direct-to-consumer and non-warranty on-demand services. These two avenues are driving FTDR's turnaround and EBIT growth opportunities. Non-warranty revenues now comprise 9% of sales, with HVAC and other on-demand repair upsells offering significant untapped potential. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-04-23 04:04
3mo ago
|
Frontdoor (FTDR) to Release Earnings on Thursday | FMP Stock News | |
|
Original source text
Posted by Defense World Staff on Apr 23rd, 2026Frontdoor (NASDAQ:FTDR – Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Thursday, April 30th. Analysts expect the company to announce earnings of $0.63 per share and revenue of $442.2790 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, April 30, 2026 at 8:30 AM ET. Frontdoor (NASDAQ:FTDR – Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.12. The firm had revenue of $433.00 million during the quarter, compared to the consensus estimate of $421.62 million. Frontdoor had a return on equity of 120.79% and a net margin of 12.18%.The company’s revenue was up 13.1% on a year-over-year basis. During the same period last year, the company earned $0.27 earnings per share. On average, analysts expect Frontdoor to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year. Frontdoor Stock Performance Shares of Frontdoor stock opened at $60.55 on Thursday. Frontdoor has a 1 year low of $40.00 and a 1 year high of $70.77. The firm’s 50-day moving average is $59.67 and its 200 day moving average is $58.86. The stock has a market cap of $4.28 billion, a price-to-earnings ratio of 17.76 and a beta of 1.41. The company has a debt-to-equity ratio of 4.73, a current ratio of 1.55 and a quick ratio of 1.55. Wall Street Analysts Forecast Growth Several research analysts have issued reports on FTDR shares. The Goldman Sachs Group raised shares of Frontdoor from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $50.00 to $67.00 in a report on Monday, March 2nd. Wall Street Zen downgraded shares of Frontdoor from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Oppenheimer restated an “outperform” rating and issued a $70.00 price objective on shares of Frontdoor in a report on Thursday, February 26th. Benchmark started coverage on Frontdoor in a research report on Thursday, March 26th. They issued a “buy” rating and a $80.00 price objective on the stock. Finally, Weiss Ratings downgraded Frontdoor from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Frontdoor currently has a consensus rating of “Moderate Buy” and an average target price of $68.60. Read Our Latest Stock Report on FTDR Institutional Trading of Frontdoor Large investors have recently made changes to their positions in the stock. Morgan Stanley lifted its position in Frontdoor by 11.5% during the fourth quarter. Morgan Stanley now owns 1,485,123 shares of the company’s stock valued at $85,677,000 after purchasing an additional 153,138 shares during the period. Invesco Ltd. grew its position in Frontdoor by 2.5% in the 4th quarter. Invesco Ltd. now owns 1,136,647 shares of the company’s stock worth $65,573,000 after purchasing an additional 27,832 shares during the period. Wasatch Advisors LP grew its position in Frontdoor by 14.9% in the 4th quarter. Wasatch Advisors LP now owns 1,112,470 shares of the company’s stock worth $64,178,000 after purchasing an additional 144,184 shares during the period. Janus Henderson Group PLC raised its stake in Frontdoor by 27.2% during the 4th quarter. Janus Henderson Group PLC now owns 902,773 shares of the company’s stock valued at $52,089,000 after buying an additional 193,256 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Frontdoor by 4.7% during the 2nd quarter. Bank of America Corp DE now owns 699,289 shares of the company’s stock valued at $41,216,000 after buying an additional 31,087 shares during the last quarter. About Frontdoor (Get Free Report) Frontdoor, Inc (NASDAQ:FTDR) is a leading provider of home service plans and repair solutions for residential property owners. The company offers contract-based coverage that helps homeowners manage the cost of repairing and replacing essential household systems and appliances, including heating and cooling, plumbing, electrical wiring, water heaters, washers, dryers, refrigerators and other major kitchen equipment. Frontdoor delivers its services through a nationwide network of independent service professionals and contractors, leveraging a cloud-based platform and call center infrastructure to coordinate service visits and process claims. Recommended Stories Five stocks we like better than Frontdoor Receive News & Ratings for Frontdoor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frontdoor and related companies with MarketBeat.com's FREE daily email newsletter. « PREVIOUS HEADLINEArcosa (ACA) Expected to Announce Quarterly Earnings on Thursday NEXT HEADLINE »Arrow Electronics (ARW) to Release Quarterly Earnings on Thursday |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-04-27 13:02
3mo ago
|
Frontdoor (FTDR) Upgraded to Buy: What Does It Mean for the Stock? | FMP Stock News | |
|
Original source text
Frontdoor (FTDR - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time. Therefore, the Zacks rating upgrade for Frontdoor basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock. Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Frontdoor imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher. Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> . Earnings Estimate Revisions for FrontdoorThis home services provider is expected to earn $4.41 per share for the fiscal year ending December 2026, which represents no year-over-year change. Analysts have been steadily raising their estimates for Frontdoor. Over the past three months, the Zacks Consensus Estimate for the company has increased 9.1%. Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term. You can learn more about the Zacks Rank here >>> The upgrade of Frontdoor to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. |
|||
|
Saved
2026-06-12 16:13
1mo ago
Published
2026-04-30 07:00
2mo ago
|
Frontdoor Continues Strong Financial Performance in First-Quarter 2026 | FMP Stock News | |
|
Original source text
Revenue Increased 6% to $451 Million;Gross Profit Margin Unchanged at 55%; Net Income Increased 11% to $41 Million, Diluted Earnings Per Share Increased 18% to $0.57; Adjusted EBITDA(1) Increased 3% to $104 Million; Reaffirming Full-Year 2026 Outlook MEMPHIS, Tenn.--(BUSINESS WIRE)--Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home warranties and new home builder warranties, today announced its first-quarter 2026 results. Financial Results Three Months Ended March 31, (In millions except as noted) 2026 2025 Change Revenue $ 451 $ 426 6 % Gross Profit 248 235 5 % Net Income 41 37 11 % Diluted Earnings per Share 0.57 0.49 18 % Adjusted Net Income(1) 53 49 8 % Adjusted Diluted Earnings per Share(1) 0.73 0.64 14 % Adjusted EBITDA(1) 104 100 3 % Home Warranties (number in millions) 2.10 2.10 0 % First-Quarter 2026 Summary Revenue increased 6% to $451 million and was comprised of 5% from higher realized price and 1% from higher volume Gross profit margin unchanged at 55% Net Income and Diluted Earnings Per Share increased 11% to $41 million and 18% to $0.57, respectively Adjusted EBITDA(1) increased 3% to $104 million First-quarter share repurchases totaled $60 million Growth in the number of home warranties in the first-year channels accelerated to 3% Reaffirming Full-Year 2026 Outlook Revenue of $2.155 billion to $2.195 billion Adjusted EBITDA(2) of $565 million to $580 million “Frontdoor delivered an excellent first quarter performance," said Chairman and Chief Executive Officer Bill Cobb. “Member count trends continued to improve, our operational foundation remains strong, and we delivered exceptional financial results while returning significant capital to shareholders through share repurchases. Looking ahead, we are reaffirming our full-year 2026 guidance based on our strong operating performance and the durability of our subscription-based business model." First-Quarter 2026 Results Revenue by Customer Channel Three Months Ended March 31, (In millions) 2026 2025 Change Renewals $ 352 $ 333 6 % Real estate (First-Year) 28 27 3 % Direct-to-consumer (First-Year) 31 32 (5 )% Other 41 33 23 % Total $ 451 $ 426 6 % Revenue increased 6% to $451 million and was comprised of a 5% increase from realized price and a 1% increase from higher volume. Renewal revenue increased 6% due to higher price realization; Real estate revenue increased 3% due to higher volume, partially offset by lower price; Direct-to-consumer revenue decreased 5% due to lower price from our promotional pricing strategy to drive new home warranty member growth, partially offset by higher volume; and Other revenue increased 23% primarily due to the growth of the HVAC upgrade program. Period-over-Period Net Income and Adjusted EBITDA(1) Bridge (In millions) Net Income Adjusted EBITDA Three Months Ended March 31, 2025 $ 37 $ 100 Impact of change in revenue 19 19 Contract claims costs (6 ) (6 ) Sales and marketing costs (6 ) (6 ) Customer service costs (2 ) (2 ) Stock-based compensation expense (3 ) — Other general and administrative costs (1 ) (1 ) Depreciation and amortization expense 2 — Interest expense 1 — Interest and net investment income (1 ) (1 ) Provision for income taxes 1 — Three Months Ended March 31, 2026 $ 41 $ 104 First-quarter 2026 Net Income increased 11% to $41 million and Adjusted EBITDA(1) increased 3% to $104 million. The table above shows the change versus the prior-year period, and includes: $19 million from higher revenue conversion(3). Contract claims costs(4) increased $6 million, excluding the impact of claims costs related to the change in revenue. Contract claims costs primarily reflects: Low-single digit cost inflation across our contractor network, replacement parts and equipment; A higher number of service requests per member, including $1 million from unfavorable weather; and Favorable claims cost development of $6 million, compared to a $7 million favorable claims cost development in the first-quarter of 2025. $6 million of higher sales and marketing costs, primarily due to increased marketing investments to drive direct-to-consumer channel growth. Cash Flow Three Months Ended March 31, (In millions) 2026 2025 Net cash provided from (used for): Operating activities $ 119 $ 124 Investing activities (7 ) 47 Financing activities (75 ) (85 ) Cash increase during the period $ 37 $ 85 Net cash provided from operating activities was $119 million for the three months ended March 31, 2026 and was comprised of $69 million in earnings adjusted for non-cash charges and $50 million in cash provided from working capital. Net cash used for investing activities was $7 million for the three months ended March 31, 2026 and was primarily comprised of capital expenditures related to technology projects. Net cash used for financing activities was $75 million for the three months ended March 31, 2026 and was primarily comprised of $60 million of share repurchases (excluding taxes and fees) and $7 million of scheduled debt payments. Free Cash Flow(1) was $114 million for the three months ended March 31, 2026. Cash as of March 31, 2026 was $603 million and was comprised of $154 million of restricted net assets and $448 million of Unrestricted Cash. Second-Quarter 2026 Outlook Revenue of $635 million to $650 million. Adjusted EBITDA(2) of $198 million to $208 million. Full-Year 2026 Outlook Revenue of $2.155 billion to $2.195 billion. Key assumptions: Realized price increase of 2% to 3%. Volume increase of 1% to 2%. Low-single digit increase in renewal channel revenue. Low-single digit decrease in direct-to-consumer channel revenue. Low-single digit increase in real estate channel revenue. $220 million to $240 million in non-warranty and other revenue. Total home warranty member count to increase approximately 1% in 2026, primarily driven by an approximately 5% increase in first-year home warranty member count. Gross profit margin of 54% to 55%. SG&A of $660 million to $680 million. Adjusted EBITDA(2) of $565 million to $580 million, and Adjusted EBITDA margin(2) of approximately 26%. Capital expenditures of $30 million to $35 million. Annual effective tax rate of approximately 25%. First-Quarter 2026 Earnings Conference Call Frontdoor has scheduled a conference call today, April 30, 2026, at 7:30 a.m. Central time (8:30 a.m. Eastern time). During the call, management will discuss the company’s operational performance and financial results for first-quarter 2026 and respond to questions from the investment community. Participants can register for the conference call by clicking https://www.webcaster5.com/Webcast/Page/3067/53785. Once completed, each participant will receive access details via email. Additionally, the conference call will be available via webcast which will include a slide presentation highlighting the company’s results. To participate via webcast and view the presentation, visit https://investors.frontdoorhome.com. The call will be available for replay for approximately 60 days. To access the replay of this call, please call 877-481-4010 and enter conference passcode 53785 (international participants: 919-882-2331, conference passcode 53785). To view a replay of the webcast, visit the company’s https://investors.frontdoorhome.com. About Frontdoor, Inc. Frontdoor and its family of brands are on a mission to make life easier for every homeowner through innovative technology and quality customer service. With over 55 years of experience, we are the leading provider of home warranties in the United States, handling approximately 3.8 million service requests for more than 2.1 million members through a network of approximately 17,000 qualified and independent service contractors. We also offer new home builder warranty solutions, which deliver value to both builders and homeowners through a suite of builder warranty products and support services. Our customizable home warranties are annual service plan agreements that cover the repair or replacement for breakdowns due to normal wear and tear of major components. We cover up to 29 home systems and appliances, including electrical, plumbing, HVAC systems, water heaters, refrigerators, dishwashers and ranges/ovens/cooktops, as well as optional coverages for pools, spas and pumps. Our home warranties provide peace of mind, budget protection, convenience, repair expertise and service guarantee. Our non-warranty services provide homeowners greater value through replacement and upgrade programs, as well as other home maintenance offerings. Our 2-10 new home builder warranty solutions offer flexible builder‑backed and insurance‑backed warranty options covering workmanship, home distribution systems and structural components. Frontdoor family of brands include American Home Shield, HSA, OneGuard, Landmark and 2-10 HBW brands. For more information about Frontdoor, Inc., please visit frontdoorhome.com. Forward-Looking Statements This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, projected future performance and any statements about Frontdoor’s plans, strategies and prospects. Forward-looking statements can be identified by the use of forward-looking terms such as “believe,” “expect,” “estimate,” “could,” “should,” “intend,” “may,” “plan,” “seek,” “anticipate,” “project,” “will,” “shall,” “would,” “aim,” or other comparable terms. These forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. Such risks and uncertainties include, but are not limited to: changes in macroeconomic conditions, including inflation, tariffs and global supply chain challenges and changing interest rates, especially as they may affect existing or new home sales, consumer confidence, demand for our services, labor availability or our costs; our ability to successfully implement our business strategies; the ability of our marketing efforts to be successful and cost-effective; our dependence on our first-year direct-to-consumer and real estate acquisition channels and our renewal channel for home warranty sales; our dependence on our existing warranty customer base, and strategic partners for non-warranty sales; changes in the source and intensity of competition in our market; our ability to attract, retain and maintain positive relations with third-party contractors and vendors; increases in parts, appliance and home system prices, and other operating costs; changes in U.S. tariffs or import/export regulations; our ability to attract and retain qualified key employees and labor availability in our customer service operations; our dependence on third-party vendors, including business process outsourcers, and third-party component suppliers; weather, including adverse conditions, seasonality, along with related environmental regulations; compliance with, or violation of, laws and regulations, including consumer protection laws, or lawsuits or other claims by third parties, increasing our legal and regulatory expenses; cybersecurity breaches, disruptions or failures in our technology systems; our ability to protect the security of personal information about our customers; technological developments in artificial intelligence; negative reputational and financial impacts resulting from acquisitions or strategic transactions; a requirement to recognize impairment charges on goodwill and intangible assets; our ability to underwrite risks accurately and to charge adequate prices to builder members, as well as our ability to effectively re-insure a large portion of those risks; the availability of reinsurance to manage a substantial portion of our potential loss exposure for our new home builder warranty business; evolving corporate governance and disclosure regulations and expectations; inappropriate use of social media by us or other parties to harm our reputation; our ability to protect our intellectual property and other material proprietary rights; third-party use of our trademarks as search engine keywords to direct our 5 potential customers to their own websites; special risks applicable to operations outside the United States by us or our business process outsource providers; the acquisition of 2-10 Home Buyers Warranty may not achieve its intended results; any liabilities, losses, or other exposures for which we do not have adequate insurance coverage, indemnification, or other protection; a return on investment in our common stock is dependent on appreciation in the price; inclusion in our certificate of incorporation a forum selection clause that could discourage an acquisition of our company or litigation against us and our directors and officers; the effects of our significant indebtedness, our ability to incur additional debt and the limitations contained in the agreements governing such indebtedness; increases in interest rates increasing the cost of servicing our indebtedness and counterparty credit risk due to instruments designed to minimize exposure to market risks; increased borrowing costs due to lowering or withdrawal of the credit ratings, outlook or watch assigned to us or our Credit Facilities; our ability to generate the significant amount of cash needed to fund our operations and service our debt obligations. We caution you that forward-looking statements are not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of operations, financial condition and liquidity, and the development of new markets or market segments in which we operate, may differ materially from those made in or suggested by the forward-looking statements contained in this news release. For a discussion of other important factors that could cause Frontdoor’s results to differ materially from those expressed in, or implied by, the forward-looking statements included in this document, refer to the risks and uncertainties detailed from time to time in Frontdoor’s periodic reports filed with the SEC, including the disclosure contained in Item 1A. Risk Factors in our 2025 Annual Report on Form 10-K filed with the SEC, as such factors may be updated from time to time in Frontdoor’s periodic filings with the SEC. Except as required by law, Frontdoor does not undertake any obligation to update or revise the forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review Frontdoor’s filings with the SEC, which are available from the SEC’s EDGAR database at sec.gov, and via Frontdoor’s website at frontdoorhome.com. Non-GAAP Financial Measures To supplement Frontdoor’s results presented in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), Frontdoor has disclosed the non-GAAP financial measures of Adjusted EBITDA, Free Cash Flow, Adjusted Net Income, Adjusted Diluted Earnings Per Share, and Unrestricted Cash. We define "Adjusted EBITDA" as net income before depreciation and amortization expense; goodwill and intangibles impairment; restructuring charges; acquisition and integration related costs; provision for income taxes; non-cash stock-based compensation expense; interest expense; loss on extinguishment of debt; and other non-operating expenses. We define “Adjusted EBITDA margin” as Adjusted EBITDA divided by revenue. We believe Adjusted EBITDA and Adjusted EBITDA margin are useful for investors, analysts and other interested parties as they facilitate company-to-company operating performance comparisons by excluding potential differences caused by variations in capital structures, taxation, the age and book depreciation of facilities and equipment, restructuring and acquisition initiatives and equity-based, long-term incentive plans. We define “Free Cash Flow” as net cash provided from operating activities less property additions. Free Cash Flow is not a measurement of our financial performance or liquidity under U.S. GAAP and does not purport to be an alternative to net cash provided from operating activities or any other performance or liquidity measures derived in accordance with U.S. GAAP. Free Cash Flow is useful as a supplemental measure of our liquidity. Management uses Free Cash Flow to facilitate company-to-company cash flow comparisons, which may vary from company-to-company for reasons unrelated to operating performance. We define “Adjusted Net Income” as net income before: amortization expense; acquisition and integration related costs; restructuring charges; loss on extinguishment of debt; other non-operating expenses; and the tax impact of the aforementioned adjustments. We believe Adjusted Net Income is useful for investors, analysts and other interested parties as it facilitates company-to-company operating performance comparisons by excluding potential differences caused by items listed in this definition. We define “Adjusted Diluted Earnings per Share” as Adjusted Net Income divided by the weighted-average diluted common shares outstanding. We define “Unrestricted Cash” as cash not subject to third-party restrictions. For additional information related to our third-party restrictions, see “Liquidity and Capital Resources — Liquidity” under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2025 Annual Report on Form 10-K filed with the SEC. See the schedules attached hereto for additional information and reconciliations of such non-GAAP financial measures. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors’ evaluation of Frontdoor’s business performance and are useful for period-over-period comparisons of the performance of Frontdoor’s business. While we believe that these non-GAAP financial measures are useful in evaluating our business, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with U.S. GAAP. In addition, these non-GAAP financial measures may not be the same as similarly entitled measures reported by other companies. © 2026 Frontdoor, Inc. All rights reserved. The following terms, which may be used in this press release, are trademarks of Frontdoor, Inc. and its subsidiaries: Frontdoor®, American Home Shield®, HSA™, 2-10 HBW® , OneGuard®, Landmark Home Warranty®, and related logos and designs. All other trademarks used herein are the property of their respective owners. Frontdoor, Inc. Consolidated Statements of Operations and Comprehensive Income (Unaudited) (In millions, except per share data) Three Months Ended March 31, 2026 2025 Revenue $ 451 $ 426 Cost of services rendered 203 191 Gross Profit 248 235 Selling and administrative expenses 162 151 Depreciation and amortization expense 20 23 Restructuring charges 1 1 Interest expense 19 19 Interest and net investment income (5 ) (6 ) Income before Income Taxes 51 48 Provision for income taxes 10 11 Net Income $ 41 $ 37 Other Comprehensive Income (Loss), Net of Income Taxes: Unrealized gain (loss) on derivative instruments, net of income taxes 4 (7 ) Total Other Comprehensive Income (Loss), Net of Income Taxes 4 (7 ) Comprehensive Income $ 45 $ 30 Earnings per Share: Basic $ 0.58 $ 0.50 Diluted $ 0.57 $ 0.49 Weighted-average Common Shares Outstanding: Basic 70.6 74.7 Diluted 72.2 76.3 Frontdoor, Inc. Condensed Consolidated Statements of Financial Position (Unaudited) (In millions, except share data) As of March 31, December 31, 2026 2025 Assets: Current Assets: Cash and cash equivalents $ 603 $ 566 Receivables, less allowance of $3 and $4, respectively 10 10 Prepaid expenses and other current assets 43 44 Assets held for sale 4 4 Total Current Assets 661 624 Other Assets: Property and equipment, net 54 57 Goodwill 959 959 Intangible assets, net 386 398 Operating lease right-of-use assets 7 7 Deferred reinsurance 65 66 Deferred customer acquisition costs 15 14 Other assets 18 17 Total Assets $ 2,164 $ 2,142 Liabilities and Shareholders' Equity: Current Liabilities: Accounts payable $ 87 $ 89 Accrued liabilities: Payroll and related expenses 32 47 Home warranty claims 64 69 Income taxes payable 35 26 Other 30 34 Deferred revenue 173 107 Current portion of long-term debt 29 29 Total Current Liabilities 451 402 Long-Term Debt 1,138 1,144 Other Long-Term Liabilities: Deferred tax liabilities, net 54 53 Operating lease liabilities 17 18 Unearned insurance premium 235 236 Long-term deferred revenue 18 19 Other long-term liabilities 22 27 Total Other Long-Term Liabilities 345 354 Commitments and Contingencies Shareholders' Equity: Common stock, $0.01 par value; 2,000,000,000 shares authorized; 89,008,654 shares issued and 70,527,394 shares outstanding as of March 31, 2026 and 88,480,560 shares issued and 70,958,215 shares outstanding as of December 31, 2025 1 1 Additional paid-in capital 199 195 Retained earnings 826 785 Accumulated other comprehensive loss (8 ) (12 ) Less treasury stock, at cost; 18,481,260 shares as of March 31, 2026 and 17,522,345 shares as of December 31, 2025 (787 ) (727 ) Total Shareholders' Equity 230 242 Total Liabilities and Shareholders' Equity $ 2,164 $ 2,142 Frontdoor, Inc. Consolidated Statements of Cash Flows (Unaudited) (In millions) Three Months Ended March 31, 2026 2025 Cash and Cash Equivalents at Beginning of Period $ 566 $ 421 Cash Flows from Operating Activities: Net Income 41 37 Adjustments to reconcile net income to net cash provided from operating activities: Depreciation and amortization expense 20 23 Deferred income tax benefit (1 ) (1 ) Stock-based compensation expense 10 8 Other (2 ) — Changes in: Receivables — 1 Prepaid expenses and other current assets 1 3 Deferred reinsurance 1 (1 ) Deferred customer acquisition costs (1 ) (1 ) Accounts payable (2 ) 5 Deferred revenue 65 61 Accrued liabilities (23 ) (25 ) Deferred insurance premiums (2 ) 2 Current income taxes 10 11 Net Cash Provided from Operating Activities 119 124 Cash Flows from Investing Activities: Purchases of property and equipment (6 ) (7 ) Purchases of short-term investments and available-for-sale securities (2 ) (6 ) Sales and maturities of available-for-sale securities — 60 Net Cash (Used for) Provided from Investing Activities (7 ) 47 Cash Flows from Financing Activities: Repayments of debt (7 ) (7 ) Repurchases of common stock (61 ) (71 ) Other financing activities (7 ) (7 ) Net Cash Used for Financing Activities (75 ) (85 ) Cash Increase During the Period 37 85 Cash and Cash Equivalents at End of Period $ 603 $ 506 Reconciliations of Non-GAAP Financial Measures The following table presents reconciliations of Net Income to Adjusted Net Income. Three Months Ended March 31, (In millions, except per share amounts) 2026 2025 Net Income $ 41 $ 37 Amortization expense 12 13 Acquisition and integration related costs 2 2 Restructuring Charges 1 1 Tax Impact of Adjustments (3 ) (3 ) Adjusted Net Income $ 53 $ 49 Adjusted Earnings per Share: Basic $ 0.75 $ 0.66 Diluted $ 0.73 $ 0.64 Weighted-average Common Shares outstanding: Basic 70.6 74.7 Diluted 72.2 76.3 The following table presents reconciliations of net cash provided from operating activities to Free Cash Flow. Three Months Ended March 31, (In millions) 2026 2025 Net cash provided from operating activities $ 119 $ 124 Property additions (6 ) (7 ) Free Cash Flow $ 114 $ 117 The following table presents reconciliations of Net Income to Adjusted EBITDA. Three Months Ended March 31, (In millions) 2026 2025 Net Income $ 41 $ 37 Depreciation and amortization expense 20 23 Restructuring charges 1 1 Acquisition and integration related costs 2 2 Provision for income taxes 10 11 Non-cash stock-based compensation expense 10 8 Interest expense 19 19 Adjusted EBITDA $ 104 $ 100 Key Business Metrics As of March 31, 2026 2025 Number of home warranties (in millions) 2.10 2.10 Renewals 1.57 1.58 First-Year Direct-To-Consumer 0.32 0.31 First-Year Real Estate 0.21 0.21 Increase (Reduction) in number of home warranties(1) 0 % 7 % Customer retention rate 79.3 % 79.9 % FTDR-Financial More News From Frontdoor, Inc. |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-04-30 09:30
2mo ago
|
Frontdoor (FTDR) Q1 Earnings and Revenues Top Estimates | FMP Stock News | |
|
Original source text
Frontdoor (FTDR - Free Report) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +11.03%. A quarter ago, it was expected that this home services provider would post earnings of $0.11 per share when it actually produced earnings of $0.23, delivering a surprise of +109.09%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Frontdoor, which belongs to the Zacks Building Products - Miscellaneous industry, posted revenues of $451 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.09%. This compares to year-ago revenues of $426 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Frontdoor shares have added about 5% since the beginning of the year versus the S&P 500's gain of 4.2%. What's Next for Frontdoor?While Frontdoor has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Frontdoor was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.75 on $641.38 million in revenues for the coming quarter and $4.41 on $2.17 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Building Products - Miscellaneous is currently in the bottom 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Crawford & Company B (CRD.B - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 4. This company is expected to post quarterly earnings of $0.20 per share in its upcoming report, which represents a year-over-year change of -4.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Crawford & Company B's revenues are expected to be $303.2 million, down 2.8% from the year-ago quarter. |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-04-30 13:21
2mo ago
|
Frontdoor, Inc. (FTDR) Q1 2026 Earnings Call Transcript | FMP Stock News | |
|
Original source text
Frontdoor, Inc. (FTDR) Q1 2026 Earnings Call Transcript |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-05-04 13:01
2mo ago
|
Here's Why Frontdoor (FTDR) is a Great Momentum Stock to Buy | FMP Stock News | |
|
Original source text
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at Frontdoor (FTDR - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Frontdoor currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period. You can see the current list of Zacks #1 Rank Stocks here >>> Set to Beat the Market? In order to see if FTDR is a promising momentum pick, let's examine some Momentum Style elements to see if this home services provider holds up. A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area. For FTDR, shares are up 11.91% over the past week while the Zacks Building Products - Miscellaneous industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 26.05% compares favorably with the industry's 7.83% performance as well. While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Frontdoor have risen 20.01%, and are up 33.59% in the last year. On the other hand, the S&P 500 has only moved 4.43% and 30.47%, respectively. Investors should also pay attention to FTDR's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. FTDR is currently averaging 632,195 shares for the last 20 days. Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with FTDR. Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. This revision helped boost FTDR's consensus estimate, increasing from $4.41 to $4.48 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period. Bottom LineTaking into account all of these elements, it should come as no surprise that FTDR is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Frontdoor on your short list. |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-06-09 08:15
1mo ago
|
American Home Shield Shares HVAC Tips to Beat the Summer Heat | FMP Stock News | |
|
Original source text
Simple Maintenance Steps Can Help Homeowners Stay Cool and Avoid Costly BreakdownsMEMPHIS, TN / ACCESS Newswire / June 9, 2026 / American Home Shield, a Frontdoor, Inc. (NASDAQ:FTDR) brand and the nation's leading provider of home warranties, is kicking off summer with HVAC tips relevant to homeowners trying to beat the heat across the nation. "Summer is here and the heat is hitting much of the nation. We want to help make sure your HVAC can run at full capacity this summer," said Ray Tong, Vice President and General Manager of home warranties for American Home Shield. Air conditioning units run 8 to 12 hours per day on average during normal summer conditions, and that can increase to 12 to 18 hours per day during extreme heat. Now is an ideal time to have your air conditioner serviced before the peak summer heat arrives. Approximately 34% of surveyed Americans say they're worried about affording electricity in the summer when air conditioning use is at its highest, according to American Home Shield survey data. Routine HVAC maintenance can help prevent major issues, keep your unit running efficiently, and save homeowners from costly repairs. Take the following steps to help ensure your unit is ready for the summer heat. Replace your air filter every 90 days and check it every 30 days to ensure proper air flow and keep your system breathing properly. Clean indoor vents to remove dust and improve circulation. To clean inside your air vents, turn off the HVAC system, remove the vent covers, and vacuum the accessible ductwork using a long hose attachment. Soak and scrub the covers in warm, soapy water, dry them completely, and replace your air filter before turning the system back on. Remove any debris, such as leaves, pollen, or twigs that could clog the unit or make it difficult to service. Test the air conditioner by turning it on to ensure your home cools effectively, the system runs quietly, and overall performance appears normal. Watch for uneven cooling, constant running, weak airflow, or a sudden spike in your energy bill. It could mean dirty filters, duct leaks, or system issues. "As a benefit to select home warranty plans, we also offer HVAC tune-ups at no additional cost for members to help ensure their unit is ready for the heat," Tong added. An American Home Shield home warranty plan is a one-year, renewable home warranty plan that repairs covered parts of home systems and appliances that break down due to normal wear and tear. If they can't repair the covered item, they'll replace it. "A home warranty can help ease the burden of unexpected breakdowns by helping homeowners avoid sudden, costly repairs," added Tong. For more information about AHS home warranty plans or the added value of video chat with an Expert as an optional benefit to select plans, visit www.ahs.com. For coverage details, including fees, limits, and limitation and exclusions, visit www.ahs.com/contracts. New Jersey Residents: The product being offered is a service contract and is separate and distinct from any product or service warranty which may be provided by the home builder or manufacturer. About Frontdoor Frontdoor and its family of brands are on a mission to make life easier for every homeowner through innovative technology and quality customer service. With over 55 years of experience, we are the leading provider of home warranties in the United States, handling approximately 3.8 million service requests for more than 2.1 million members through a network of approximately 17,000 qualified and independent service contractors. We also offer new home builder warranty solutions, which deliver value to both builders and homeowners through a suite of builder warranty products and support services. Our customizable home warranties are annual service plan agreements that cover the repair or replacement for breakdowns due to normal wear and tear of major components. We cover up to 29 home systems and appliances, including electrical, plumbing, HVAC systems, water heaters, refrigerators, dishwashers and ranges/ovens/cooktops, as well as optional coverages for pools, spas and pumps. Our home warranties provide peace of mind, budget protection, convenience, repair expertise and service guarantee. Our non-warranty services provide homeowners greater value through replacement and upgrade programs, as well as other home maintenance offerings. Our 2-10 new home builder warranty solutions offer flexible builder‑backed and insurance‑backed warranty options covering workmanship, home distribution systems and structural components. Frontdoor family of brands include American Home Shield, HSA, OneGuard, Landmark and 2-10 HBW brands. For more information about Frontdoor, Inc., please visit frontdoorhome.com. Media Alison Bishop 901-701-5198 [email protected] FTDR-Company SOURCE: Frontdoor |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-04-13 19:01
3mo ago
|
Blackbaud Inc (BLKB) Shares Surge 5.5% -- What GF Score of 63 Tells Investors | FMP Stock News | |
|
Original source text
On April 13, 2026, Blackbaud Inc (BLKB) shares rose 5.5% to a current price of $36.16, amidst a challenging price performance context. Over the past month, the |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-04-15 09:00
3mo ago
|
Blackbaud Announces Date of First Quarter FY2026 Financial Results | FMP Stock News | |
|
Original source text
, /PRNewswire/ -- Blackbaud (NASDAQ: BLKB), the world's leading provider of AI-powered solutions for social impact, will report its first quarter FY2026 financial results at 8:00 a.m. ET on Wednesday, April 29, before the U.S. financial markets open for trading. In conjunction with this announcement, Blackbaud will host a conference call at 8:00 a.m. ET to discuss the company's financial results.Event: Blackbaud's First Quarter FY2026 Financial Results Conference Call Date: Wednesday, April 29, 2026 Time: 8:00 a.m. ET Live Webcast: investor.blackbaud.com Live Dial-In: 1-877-407-3088 or +1 201-389-0927 A webcast will be available and archived on Blackbaud's investor webpage following the call. About Blackbaud Blackbaud (NASDAQ: BLKB) is the world's leading provider of AI-powered solutions for social impact. Serving nonprofits, educational institutions, companies committed to corporate social responsibility, and individual change makers, Blackbaud propels impact at scale with the sector's most intelligent solutions for fundraising, nonprofit financial management, digital giving, grant making, corporate social responsibility, and education management. With the deepest expertise powered by the world's largest philanthropic data set, the most connected workflows, and the most powerful impact network, Blackbaud's solutions are building a future where resources are unleashed at the speed of need. Blackbaud has been recognized by Fast Company, Newsweek, Quartz, Forbes and more for AI innovation, responsible leadership and workplace excellence. Blackbaud has operations in the United States, Australia, Canada, Costa Rica, India and the United Kingdom, supporting users in 100+ countries. Learn more at www.blackbaud.com or follow us on X/Twitter, LinkedIn, Instagram and Facebook. Media Inquiries [email protected] Forward-looking Statements Except for historical information, all of the statements, expectations and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties, including statements regarding expected benefits of products and product features. Although Blackbaud attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors that could cause results to differ materially include the following: general economic risks; uncertainty regarding increased business and renewals from existing customers; continued success in sales growth; management of integration of acquired companies and other risks associated with acquisitions; risks associated with successful implementation of multiple integrated software products; the ability to attract and retain key personnel; risks associated with management of growth; lengthy sales and implementation cycles; technological changes that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for Blackbaud, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from Blackbaud's investor relations department. All Blackbaud product names appearing herein are trademarks or registered trademarks of Blackbaud, Inc. SOURCE Blackbaud |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-04-16 03:20
3mo ago
|
Blackbaud, Inc. (NASDAQ:BLKB) Short Interest Up 30.2% in March | FMP Stock News | |
|
Original source text
Posted by Defense World Staff on Apr 16th, 2026Blackbaud, Inc. (NASDAQ:BLKB – Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 2,457,902 shares, a growth of 30.2% from the March 15th total of 1,888,251 shares. Currently, 5.5% of the shares of the company are sold short. Based on an average daily trading volume, of 614,824 shares, the days-to-cover ratio is currently 4.0 days. Blackbaud Trading Up 5.8% Shares of BLKB opened at $37.96 on Thursday. The business’s 50-day moving average price is $43.98 and its 200-day moving average price is $54.75. Blackbaud has a twelve month low of $33.95 and a twelve month high of $74.88. The stock has a market cap of $1.74 billion, a PE ratio of 15.95, a P/E/G ratio of 1.24 and a beta of 1.18. The company has a quick ratio of 0.79, a current ratio of 0.79 and a debt-to-equity ratio of 12.78. Blackbaud (NASDAQ:BLKB – Get Free Report) last announced its quarterly earnings results on Tuesday, February 10th. The technology company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.04. Blackbaud had a return on equity of 175.57% and a net margin of 10.19%.The firm had revenue of $295.26 million for the quarter, compared to analysts’ expectations of $292.71 million. During the same period in the prior year, the business posted $1.08 earnings per share. The company’s revenue was down 2.3% on a year-over-year basis. Blackbaud has set its FY 2026 guidance at 5.150-5.250 EPS. On average, equities analysts forecast that Blackbaud will post 3.05 EPS for the current fiscal year. Insider Buying and Selling In related news, EVP Kevin P. Gregoire sold 2,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $50.02, for a total value of $100,040.00. Following the transaction, the executive vice president directly owned 135,194 shares of the company’s stock, valued at approximately $6,762,403.88. The trade was a 1.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David J. Benjamin sold 14,349 shares of the business’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $47.47, for a total transaction of $681,147.03. Following the completion of the transaction, the executive vice president directly owned 73,124 shares in the company, valued at $3,471,196.28. This trade represents a 16.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 39,801 shares of company stock valued at $1,893,874. 1.97% of the stock is owned by insiders. Institutional Inflows and Outflows Institutional investors have recently modified their holdings of the stock. Rothschild Investment LLC increased its position in shares of Blackbaud by 589.0% in the fourth quarter. Rothschild Investment LLC now owns 565 shares of the technology company’s stock worth $36,000 after purchasing an additional 483 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Blackbaud by 380.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 615 shares of the technology company’s stock worth $39,000 after purchasing an additional 487 shares during the last quarter. TD Private Client Wealth LLC increased its position in shares of Blackbaud by 4,300.0% in the fourth quarter. TD Private Client Wealth LLC now owns 616 shares of the technology company’s stock worth $39,000 after purchasing an additional 602 shares during the last quarter. Quarry LP bought a new position in shares of Blackbaud in the third quarter worth approximately $46,000. Finally, Kestra Advisory Services LLC bought a new position in shares of Blackbaud in the fourth quarter worth approximately $47,000. 94.21% of the stock is currently owned by institutional investors. Analysts Set New Price Targets Several research firms have commented on BLKB. Robert W. Baird set a $60.00 price objective on shares of Blackbaud in a report on Wednesday, February 11th. Zacks Research downgraded shares of Blackbaud from a “strong-buy” rating to a “hold” rating in a report on Monday. Raymond James Financial set a $60.00 price objective on shares of Blackbaud in a report on Tuesday, February 10th. Evercore set a $55.00 price objective on shares of Blackbaud in a report on Wednesday, February 11th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Blackbaud in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Blackbaud has an average rating of “Reduce” and an average target price of $56.25. View Our Latest Research Report on BLKB Blackbaud Company Profile (Get Free Report) Blackbaud, Inc is a leading provider of cloud software, services and data intelligence solutions designed specifically for the social good community. The company’s main offerings include fundraising and relationship management platforms, financial management systems, grant and award management tools, and advanced analytics. Its flagship products—such as Raiser’s Edge NXT, Blackbaud Financial Edge NXT and Blackbaud NetCommunity—help nonprofit organizations, educational institutions, healthcare providers and foundations streamline donor engagement, optimize financial operations and measure program impact. Founded in 1981 and headquartered in Charleston, South Carolina, Blackbaud has grown from a small technology startup into a global specialist in nonprofit software. See Also Five stocks we like better than Blackbaud Receive News & Ratings for Blackbaud Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blackbaud and related companies with MarketBeat.com's FREE daily email newsletter. « PREVIOUS HEADLINEShort Interest in Global X Autonomous & Electric Vehicles ETF (NASDAQ:DRIV) Grows By 29.4% NEXT HEADLINE »Allison Transmission Holdings, Inc. (NYSE:ALSN) Short Interest Update |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-04-24 18:14
3mo ago
|
Blackbaud Inc (BLKB) Shares Surge 3.6% -- What GF Score of 65 Tells Investors | FMP Stock News | |
|
Original source text
Valuation Assessment of Blackbaud Inc (BLKB) On April 24, 2026, Blackbaud Inc (BLKB) shares rose 3.6%, closing at $37.49. The stock has experienced significant |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-04-27 09:32
3mo ago
|
Blackbaud Highlights AI Capabilities Transforming Fundraising at AFP ICON 2026 | FMP Stock News | |
|
Original source text
As the Presenting Sponsor of the Association of Fundraising Professionals' Flagship Event, Blackbaud will Enable Fundraisers with the Power of Responsible AI, /PRNewswire/ -- Blackbaud (NASDAQ: BLKB), the world's leading provider of AI-powered solutions for social impact, is proud to once again serve as the presenting sponsor of AFP ICON, the flagship global conference of the Association of Fundraising Professionals (AFP), taking place this week in San Diego. As the longstanding category leader in social impact technology, Blackbaud has a proven history of supporting and advancing the fundraising profession, partnering with social impact organizations to advance global missions. Blackbaud is now ushering the sector into a new era of impact, equipping fundraisers with purpose-built, responsible AI tools that help them navigate increasing complexity, meet donor expectations, and accelerate their outcomes. According to research from the Blackbaud Institute, the typical nonprofit saw approximately 4.3% revenue growth last year, but growth was concentrated among organizations with greater capacity. When resources are scarce, adding capacity can be a challenge, which is why technology that has the power to amplify fundraising results is critical. "Fundraisers are being asked to do more than ever. They need to build deeper relationships, personalize engagement at scale, and raise more, often with limited time and resources," said Tiffany Crumpton, vice president, head of donor management and fundraising products, Blackbaud. "Our commitment is to help advance the profession by equipping fundraisers with powerful solutions that have intelligent capabilities embedded directly in their day-to-day workflows to scale personalization, and translate philanthropic insight into real-world impact. AFP is a critical partner in shaping the future of fundraising, and together we share a deep commitment to trust, ethics, education, and progress across the sector." Responsible AI That's Propelling Fundraising Forward At AFP ICON 2026, Blackbaud will showcase how its AI solutions designed specifically for fundraising and embedded directly into existing workflows are enabling teams to work smarter, expand their capacity, build stronger donor relationships, and accelerate impact. Blackbaud will highlight its latest AI innovations including: The Development Agent, Blackbaud's first Agent for Good™: This autonomous, AI-powered digital teammate is the first-ever expert agent to be embedded in a dedicated social impact platform. Working alongside Blackbaud Raiser's Edge NXT® users, the Development Agent identifies, cultivates and engages donors with timely, individualized and brand-aligned outreach that enables fundraising teams to expand their capacity for donor engagement and grow giving at scale. Intelligent Assistance for Raiser's Edge NXT: These AI features help fundraisers work more efficiently by automating workflows and delivering advanced analytics to inform smarter decisions. AI‑enhanced intelligent assistance in Raiser's Edge NXT surfaces strategic insights and recommended actions, boosting productivity while keeping fundraisers firmly in control. Action Strategies in Raiser's Edge NXT: New Action Strategies reduce the prep time required for donor outreach by compiling relevant donor context—recent activity, engagement signals, preferences, and recommended next steps—into concise, easy-to-read briefings within existing workflows. This amplifies fundraisers' expertise and gives them more time to spend building relationships that drive philanthropic outcomes. Blackbaud's commitment to building trustworthy, industry‑specific AI at scale recently earned recognition from Microsoft. As a Microsoft Solutions Partner, Blackbaud has achieved the Certified Software for Non‑Profit AI designation for Raiser's Edge NXT, signaling that its AI capabilities meet Microsoft's standards for enterprise-grade security, interoperability, and customer value. This is an important differentiator for customers seeking confidence as they adopt agentic and generative AI in mission-critical environments. Blackbaud Raiser's Edge NXT, Blackbaud Development Agent and other purpose-built solutions are available as transactable offers through Microsoft's Commercial Marketplace. The Power of Connected Systems AFP ICON attendees can also learn how their organizations can benefit from Blackbaud's unique network effect as the provider that connects the entire social impact ecosystem, from fundraising to corporate impact to financial management and more. Tapping into Workplace Giving: With the Blackbaud Verified Network, nonprofits can boost their visibility to over 500 companies and nine million employees who partner with YourCause® from Blackbaud® to power their purpose in employee giving, volunteering and community investment initiatives. Being part of the Network builds credibility with donors and unlocks the fastest donation processing in the market. Because of the connection between YourCause and Blackbaud Integrated Payments, Blackbaud's nonprofit customers can receive these donations exponentially faster with Blackbaud's exclusive Expedited Giving feature. Connecting the Back Office: With key fundraising products like Blackbaud Raiser's Edge NXT and Blackbaud Enterprise Fundraising CRM™ connecting directly to Blackbaud Financial Edge NXT®, teams can gain greater visibility, accountability and confidence as they scale impact. A Longstanding Partnership with AFP Together, Blackbaud and AFP invest in professional development, ethical standards and innovations that strengthen the global fundraising community and help nonprofit organizations thrive. Blackbaud is proud to support AFP's mission through conference sponsorship, educational programming, research and ongoing collaboration. "Blackbaud has long been a valued partner to AFP and the fundraising profession," said Chris Amos, senior director of business development, AFP. "Their continued investment in education, innovation and responsible technology—and their commitment to empowering fundraisers—aligns closely with our mission to advance philanthropy and support professionals at every stage of their careers." On the Ground at AFP ICON 2026 Conference attendees can connect with Blackbaud experts through conference sessions featuring discussions on navigating uncertainty and using data and AI responsibly, through learning labs featuring practical, hands-on fundraising strategies, and through live demos in the Blackbaud booth showcasing the latest AI-enabled features and workflows. Visit the Blackbaud booth (#501) to learn more. About Blackbaud Blackbaud (NASDAQ: BLKB) is the world's leading provider of AI-powered solutions for social impact. Serving nonprofits, educational institutions, companies committed to corporate social responsibility, and individual change makers, Blackbaud propels impact at scale with the sector's most intelligent solutions for fundraising and engagement, education solutions, financial management and CSR and grantmaking. With the deepest expertise powered by the world's largest philanthropic data set, the most connected workflows, and the most powerful impact network, Blackbaud's solutions are building a future where resources are unleashed at the speed of need. Blackbaud has been recognized by Fast Company, Newsweek, Quartz, Forbes and more for AI innovation, responsible leadership and workplace excellence. Blackbaud has operations in the United States, Australia, Canada, Costa Rica, India and the United Kingdom, supporting users in 100+ countries. Learn more at www.blackbaud.com or follow us on X/Twitter, LinkedIn, Instagram and Facebook. Media Inquiries [email protected] Forward-looking Statements Except for historical information, all of the statements, expectations and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties, including statements regarding expected benefits of products and product features. Although Blackbaud attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors that could cause results to differ materially include the following: general economic risks; uncertainty regarding increased business and renewals from existing customers; continued success in sales growth; management of integration of acquired companies and other risks associated with acquisitions; risks associated with successful implementation of multiple integrated software products; the ability to attract and retain key personnel; risks associated with management of growth; lengthy sales and implementation cycles; technological changes that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for Blackbaud, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from Blackbaud's investor relations department. All Blackbaud product names appearing herein are trademarks or registered trademarks of Blackbaud, Inc. SOURCE Blackbaud |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-04-29 07:00
3mo ago
|
Blackbaud Announces 2026 First Quarter Results | FMP Stock News | |
|
Original source text
Company Launches Its First Agent For Good™ Agentic AI Solution for the Social Impact Sector , /PRNewswire/ -- Blackbaud (NASDAQ: BLKB), the leader in AI for social impact, today announced financial results for its first quarter ended March 31, 2026. "We're off to a strong start in 2026, and our execution continues to reinforce Blackbaud's clear leadership in the social impact software market," said Mike Gianoni, president, CEO and vice chairman of the board of directors, Blackbaud. "With more than 70 new AI capabilities embedded across our products, we have now taken the next step and launched the first of many planned new agentic AI solutions, the Development Agent. Early demand has been exceptional, customer interest is high, and momentum is building. This strong first quarter reinforces our confidence in our AI-powered roadmap and positions Blackbaud well for 2026 and beyond as we pursue our aspirational goals." First Quarter 2026 Results Compared to First Quarter 2025 Results: GAAP total revenue was $281.1 million, up 4.2% and non-GAAP organic revenue increased 4.2%. GAAP recurring revenue was $276.5 million, up 5.0% and represented 98.3% of total revenue. Non-GAAP organic recurring revenue increased 5.0%. GAAP income from operations was $51.4 million, with GAAP operating margin of 18.3%, an increase of 1,100 basis points. Non-GAAP income from operations was $83.4 million, with non-GAAP operating margin of 29.6%, an increase of 120 basis points. GAAP net income was $31.1 million, with GAAP diluted earnings per share of $0.67, up $0.58 per share. Non-GAAP net income was $52.6 million, with non-GAAP diluted earnings per share of $1.14, up $0.19 per share. Non-GAAP adjusted EBITDA was $98.7 million, up $6.6 million, with non-GAAP adjusted EBITDA margin of 35.1%, an increase of 100 basis points. Rule of 40 score was 39.3%. GAAP net cash provided by operating activities was $51.5 million, an increase of $50.1 million, with GAAP operating cash flow margin of 18.3%, an increase of 1,780 basis points. Non-GAAP free cash flow was $37.0 million, an increase of $49.3 million, with non-GAAP free cash flow margin of 13.2%, an increase of 1,770 basis points. "We began 2026 with disciplined execution against our operating plan, while continuing to invest in innovation to support both performance today and the opportunities ahead," said Chad Anderson, executive vice president and CFO, Blackbaud. "The quarter reflects the strength of our financial model—driving growth, expanding margins, improving EPS, and generating strong free cash flow. We continued our purposeful capital allocation strategy, repurchasing approximately 4.5% of our shares outstanding at the end of 2025 inclusive of net share settlement of employee stock compensation, while maintaining financial flexibility. This combination of execution, reinvestment, and disciplined capital deployment underpins our ability to deliver long‑term value." An explanation of all non-GAAP financial measures referenced in this press release, including the Rule of 40, is included below under the heading "Non-GAAP Financial Measures." A reconciliation of the company's non-GAAP financial measures to their most directly comparable GAAP measures has been provided in the financial statement tables included below in this press release. Recent Company Highlights Blackbaud launched its first Agent for Good™, the Development Agent, which is the first-ever expert agent to be embedded in a dedicated social impact platform and is designed to help personalize donor engagement and grow giving at scale. The Development Agent is available to Raiser's Edge NXT® customers in the U.S., with availability internationally and in other products to follow. Blackbaud highlighted customer outcomes that underline the real-world impact of its solutions and showcase the differentiated power of Blackbaud's specialized domain expertise. Chief Data and AI Officer Carrie Cobb shared how Blackbaud is approaching responsible AI, through engagement, shared learning, and cross‑sector leadership. As the presenting sponsor of the Association of Fundraising Professionals (AFP) ICON conference, Blackbaud shared how it is ushering the sector into a new era of social impact, equipping fundraisers with purpose-built, responsible AI tools that help them navigate increasing complexity, meet donor expectations, and accelerate their outcomes. At its annual Corporate Social Impact Summit, Blackbaud convened hundreds of corporate and social good leaders for thought‑provoking sessions from industry experts and an exclusive preview of upcoming innovation across the YourCause® from Blackbaud® platform, including advancements in AI capabilities, faster donation processing, and social impact reporting. The company announced open registration for bbcon, its annual technology conference, taking place in Columbus, Ohio, Sept. 29–Oct. 1 this year, with global events following in London and Sydney. Visit www.blackbaud.com/newsroom for more information about Blackbaud's recent highlights. Financial Outlook Blackbaud today reaffirmed its 2026 full year financial guidance: GAAP revenue of $1.173 billion to $1.179 billion Non-GAAP adjusted EBITDA of $430 million to $438 million Non-GAAP diluted earnings per share of $5.15 to $5.25 Non-GAAP free cash flow of $280 million to $290 million Included in its 2026 full year financial guidance are the following updated assumptions: Non-GAAP annualized effective tax rate is expected to be approximately 24.5% Interest expense for the year is expected to be approximately $62 million to $66 million Diluted weighted average shares outstanding for the year are expected to be approximately 45.0 million to 46.0 million Capital expenditures for the year are expected to be approximately $60 million to $70 million, including approximately $52 million to $62 million of capitalized software development costs Blackbaud has not reconciled forward-looking full-year non-GAAP financial measures contained in this news release to their most directly comparable GAAP measures, as permitted by Item 10(e)(1)(i)(B) of Regulation S-K. Such reconciliations would require unreasonable efforts at this time to estimate and quantify with a reasonable degree of certainty various necessary GAAP components, including for example those related to compensation, acquisition transactions and integration, tax items or others that may arise during the year. These components and other factors could materially impact the amount of the future directly comparable GAAP measures, which may differ significantly from their non-GAAP counterparts. Stock Repurchase Program As of March 31, 2026, Blackbaud had approximately $878 million remaining under its common stock repurchase program that was expanded, replenished and reauthorized in December 2025. Based on our current plans, we expect total repurchases during 2026 to represent between 5.0% and 10.0% of our outstanding common stock as of December 31, 2025. Conference Call Details What: Blackbaud's 2026 First Quarter Conference Call When: April 29, 2026 Time: 8:00 a.m. (Eastern Time) Live Call: 1-877-407-3088 (US/Canada) Webcast: Blackbaud's Investor Relations Webpage About Blackbaud Blackbaud (NASDAQ: BLKB) is the world's leading provider of AI-powered solutions for social impact. Serving nonprofits, educational institutions, companies committed to corporate social responsibility and individual change makers, Blackbaud propels impact at scale with the sector's most intelligent solutions for fundraising and engagement, education solutions, financial management and CSR and grantmaking. With the deepest expertise powered by the world's largest philanthropic data set, the most connected workflows, and the most powerful impact network, Blackbaud's solutions are building a future where resources are unleashed at the speed of need. Blackbaud has been recognized by Fast Company, Newsweek, Quartz, Forbes and more for AI innovation, responsible leadership and workplace excellence. Blackbaud has operations in the United States, Australia, Canada, Costa Rica, India and the United Kingdom, supporting users in 100+ countries. Learn more at www.blackbaud.com, or follow us on X/Twitter, LinkedIn, Instagram, and Facebook. Investor Contact [email protected] Media Contact [email protected] Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this news release are forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the predictability of our financial condition and results of operations. These statements involve a number of risks and uncertainties. Although Blackbaud attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors that could cause results to differ materially include the following: management of integration of acquired companies; uncertainty regarding increased business and renewals from existing customers; a shifting revenue mix that may impact gross margin; continued success in sales growth; risks related to the development, deployment, regulation, security, market adoption and perception of artificial intelligence technologies; cybersecurity and data protection risks and related liabilities; potential litigation involving us; and the other risk factors set forth from time to time in the SEC filings for Blackbaud, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from Blackbaud's investor relations department. Blackbaud assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Trademarks All Blackbaud product names appearing herein are trademarks or registered trademarks of Blackbaud, Inc. Non-GAAP Financial Measures Blackbaud has provided in this release financial information that has not been prepared in accordance with GAAP. Blackbaud uses non-GAAP financial measures internally in analyzing its operational performance. Accordingly, Blackbaud believes these non-GAAP measures are useful to investors, as a supplement to GAAP measures, in evaluating its ongoing operational performance and trends and in comparing its financial results from period-to-period with other companies in Blackbaud's industry, many of which present similar non-GAAP financial measures to investors. However, these non-GAAP financial measures may not be completely comparable to similarly titled measures of other companies due to potential differences in the exact method of calculation between companies. The non-GAAP financial measures discussed above exclude the impact of certain transactions that Blackbaud believes are not directly related to its operating performance in any particular period, but are for its long-term benefit over multiple periods. Blackbaud believes these non-GAAP financial measures reflect its ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of trends in its business. While Blackbaud believes these non-GAAP measures provide useful supplemental information, non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliations of these non-GAAP measures to their most directly comparable GAAP financial measures. Non-GAAP free cash flow is defined as operating cash flow less capital expenditures, including costs required to be capitalized for software development, and capital expenditures for property and equipment. Blackbaud believes non-GAAP free cash flow provides a useful measure of the company's operating performance. Non-GAAP free cash flow is not intended to represent and should not be viewed as the amount of residual cash flow available for discretionary expenditures. In addition, Blackbaud uses non-GAAP organic revenue growth, non-GAAP organic revenue growth on a constant currency basis, non-GAAP organic recurring revenue growth and non-GAAP organic recurring revenue growth on a constant currency basis, in analyzing its operating performance. Blackbaud believes that these non-GAAP measures are useful to investors, as a supplement to GAAP measures, for evaluating the periodic growth of its business on a consistent basis. Each of these measures excludes incremental acquisition-related revenue attributable to companies, if any, acquired in the current fiscal year. For companies acquired in the immediately preceding fiscal year, each of these measures reflects presentation of full-year incremental non-GAAP revenue derived from such companies as if they were combined throughout the prior period. In addition, each of these measures excludes prior period revenue associated with divested businesses, if any. The exclusion of the prior period revenue is to present the results of the divested businesses within the results of the combined company for the same period of time in both the prior and current periods. Blackbaud believes this presentation provides a more comparable representation of its current business' organic revenue growth and revenue run-rate. Rule of 40 is defined as non-GAAP organic revenue growth plus non-GAAP adjusted EBITDA margin. Non-GAAP adjusted EBITDA is defined as GAAP net income plus interest, net; income tax provision (benefit); depreciation; amortization of intangible assets from business combinations; amortization of software development costs; stock-based compensation expense; Global Capabilities Center ("GCC") workforce transition costs; acquisition and disposition-related costs; and Security Incident-related costs. Blackbaud, Inc. Consolidated Balance Sheets (Unaudited) (dollars in thousands, except per share amounts) March 31, 2026 December 31, 2025 Assets Current assets: Cash and cash equivalents $ 34,096 $ 38,914 Restricted cash 418,671 720,061 Accounts receivable, net of allowance of $5,924 and $5,876 at March 31, 2026 and December 31, 2025, respectively 75,691 80,517 Customer funds receivable 7,605 1,308 Prepaid expenses and other current assets 106,158 89,290 Total current assets 642,221 930,090 Property and equipment, net 85,053 85,076 Software development costs, net 156,628 155,842 Goodwill 1,055,777 1,056,815 Intangible assets, net 99,279 106,654 Other assets 70,340 56,205 Total assets $ 2,109,298 $ 2,390,682 Liabilities and stockholders' equity Current liabilities: Trade accounts payable $ 46,884 $ 27,344 Accrued expenses and other current liabilities 37,515 43,272 Due to customers 425,124 719,833 Debt, current portion 23,160 22,660 Deferred revenue, current portion 333,996 368,986 Total current liabilities 866,679 1,182,095 Debt, net of current portion 1,163,182 1,087,037 Deferred tax liability 27,333 21,981 Deferred revenue, net of current portion 6,054 2,778 Other liabilities 11,496 11,737 Total liabilities 2,074,744 2,305,628 Commitments and contingencies Stockholders' equity: Preferred stock; 20,000,000 shares authorized, none outstanding — — Common stock, $0.001 par value; 180,000,000 shares authorized, 74,015,631 and 72,312,354 shares issued at March 31, 2026 and December 31, 2025, respectively; 46,297,968 and 46,705,325 shares outstanding at March 31, 2026 and December 31, 2025, respectively 74 72 Additional paid-in capital 1,415,521 1,391,641 Treasury stock, at cost; 27,717,663 and 25,607,029 shares at March 31, 2026 and December 31, 2025, respectively (1,423,843) (1,316,224) Accumulated other comprehensive loss (3,850) (5,948) Retained earnings 46,652 15,513 Total stockholders' equity 34,554 85,054 Total liabilities and stockholders' equity $ 2,109,298 $ 2,390,682 Blackbaud, Inc. Consolidated Statements of Comprehensive Income (Unaudited) (dollars in thousands, except per share amounts) Three months ended March 31, 2026 2025 Revenue $ 281,140 $ 269,936 Cost of revenue 114,581 114,815 Gross profit 166,559 155,121 Operating expenses Sales, marketing and customer success 47,349 44,644 Research and development 36,916 33,559 General and administrative 30,261 56,679 Amortization of intangible assets 588 534 Total operating expenses 115,114 135,416 Income from operations 51,445 19,705 Interest expense (16,036) (16,945) Other income, net 2,396 2,105 Income before provision for income taxes 37,805 4,865 Income tax provision 6,666 542 Net income $ 31,139 $ 4,323 Earnings per share Basic $ 0.68 $ 0.09 Diluted $ 0.67 $ 0.09 Common shares and equivalents outstanding Basic weighted average shares 45,562,304 48,429,061 Diluted weighted average shares 46,351,379 49,445,079 Other comprehensive income (loss) Foreign currency translation adjustment $ (1,480) $ 3,259 Unrealized gain (loss) on derivative instruments, net of tax 3,578 (6,692) Total other comprehensive income (loss) 2,098 (3,433) Comprehensive income $ 33,237 $ 890 Blackbaud, Inc. Consolidated Statements of Cash Flows (Unaudited) Three months ended March 31, (dollars in thousands) 2026 2025 Cash flows from operating activities Net income $ 31,139 $ 4,323 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 20,551 21,647 Net provision for credit losses and sales returns 1,128 788 Stock-based compensation expense 23,880 22,170 Deferred taxes 4,257 (221) Amortization of deferred financing costs and discount 486 699 Other non-cash adjustments — (5,384) Changes in operating assets and liabilities, net of acquisition and disposal of businesses: Accounts receivable 3,613 4,770 Prepaid expenses and other assets (18,048) (5,192) Trade accounts payable 19,258 (4,651) Accrued expenses and other liabilities (3,186) (8,134) Deferred revenue (31,619) (29,427) Net cash provided by operating activities 51,459 1,388 Cash flows from investing activities Purchase of property and equipment (1,668) (688) Capitalized software development costs (12,798) (12,970) Cash used in disposition of business — (12,235) Net cash used in investing activities (14,466) (25,893) Cash flows from financing activities Proceeds from issuance of debt 139,900 216,200 Payments on debt (74,968) (85,523) Employee taxes paid for withheld shares upon equity award settlement (25,112) (37,948) Change in due to customers (294,090) (320,248) Change in customer funds receivable (6,395) (2,483) Purchase of treasury stock, including excise tax payments (82,103) (100,030) Net cash used in financing activities (342,768) (330,032) Effect of exchange rate on cash, cash equivalents and restricted cash (433) 1,668 Net decrease in cash, cash equivalents and restricted cash (306,208) (352,869) Cash, cash equivalents and restricted cash, beginning of period 758,975 809,512 Cash, cash equivalents and restricted cash, end of period $ 452,767 $ 456,643 The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown above in the consolidated statements of cash flows: (dollars in thousands) March 31, 2026 December 31, 2025 Cash and cash equivalents $ 34,096 $ 38,914 Restricted cash 418,671 720,061 Total cash, cash equivalents and restricted cash in the statement of cash flows $ 452,767 $ 758,975 Blackbaud, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (dollars in thousands, except per share amounts) Three months ended March 31, 2026 2025 GAAP Revenue $ 281,140 $ 269,936 GAAP gross profit $ 166,559 $ 155,121 GAAP gross margin 59.2 % 57.5 % Non-GAAP adjustments: Add: Stock-based compensation expense 3,087 2,698 Add: Amortization of intangibles from business combinations 6,267 7,052 Add: GCC workforce transition costs(1) 275 — Subtotal 9,629 9,750 Non-GAAP gross profit $ 176,188 $ 164,871 Non-GAAP gross margin 62.7 % 61.1 % GAAP income from operations $ 51,445 $ 19,705 GAAP operating margin 18.3 % 7.3 % Non-GAAP adjustments: Add: Stock-based compensation expense 23,880 22,170 Add: Amortization of intangibles from business combinations 6,855 7,586 Add: GCC workforce transition costs(1) 1,026 — Add: Acquisition and disposition-related costs(2) 147 25,132 Add: Security Incident-related costs — 2,180 Subtotal 31,908 57,068 Non-GAAP income from operations $ 83,353 $ 76,773 Non-GAAP operating margin 29.6 % 28.4 % GAAP income before provision for income taxes $ 37,805 $ 4,865 GAAP net income $ 31,139 $ 4,323 Shares used in computing GAAP diluted earnings per share 46,351,379 49,445,079 GAAP diluted earnings per share $ 0.67 $ 0.09 Non-GAAP adjustments: Add: GAAP income tax provision 6,666 542 Add: Total non-GAAP adjustments affecting income from operations 31,908 57,068 Non-GAAP income before provision for income taxes 69,713 61,933 Assumed non-GAAP income tax provision(3) 17,080 15,174 Non-GAAP net income $ 52,633 $ 46,759 Shares used in computing non-GAAP diluted earnings per share 46,351,379 49,445,079 Non-GAAP diluted earnings per share $ 1.14 $ 0.95 (1) GCC workforce transition costs represent severance and other costs incurred in connection with the transition of certain roles to our Global Capability Center in Hyderabad, India. (2) Includes charges of $24.3 million incurred during the three months ended March 31, 2025 related to the release from our lease for office space in Washington, DC. (3) We use a non-GAAP effective tax rate of 24.5% when calculating non-GAAP net income and non-GAAP diluted earnings per share. We base this rate on our estimated annual GAAP income tax rate, adjusted for items excluded from GAAP income when calculating non-GAAP income and for significant nonrecurring tax adjustments. We review this non-GAAP tax rate annually to determine whether it remains appropriate for evaluating our financial performance. In conducting this review, we consider our GAAP annual effective tax rate, changes in tax legislation, non-GAAP adjustments, and shifts in the geographic mix of revenues and expenses. We also evaluate other factors that we deem significant. Because the tax treatment of non-GAAP adjustments differs from GAAP and because of our methodology for estimating the annual tax rate, the non-GAAP tax rate may differ from the GAAP tax rate and from our actual tax liabilities. Blackbaud, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (dollars in thousands) Three months ended March 31, 2026 2025 GAAP revenue $ 281,140 $ 269,936 GAAP revenue growth 4.2 % Less: Non-GAAP revenue from divested businesses(1) — — Non-GAAP organic revenue(2) $ 281,140 $ 269,936 Non-GAAP organic revenue growth 4.2 % Non-GAAP organic revenue(2) $ 281,140 $ 269,936 Foreign currency impact on non-GAAP organic revenue(3) (2,240) — Non-GAAP organic revenue on constant currency basis(3) $ 278,900 $ 269,936 Non-GAAP organic revenue growth on constant currency basis 3.3 % GAAP recurring revenue $ 276,485 $ 263,325 GAAP recurring revenue growth 5.0 % Less: Non-GAAP recurring revenue from divested businesses(1) — — Non-GAAP organic recurring revenue(2) $ 276,485 $ 263,325 Non-GAAP organic recurring revenue growth 5.0 % Non-GAAP organic recurring revenue(2) $ 276,485 $ 263,325 Foreign currency impact on non-GAAP organic recurring revenue(3) (2,198) — Non-GAAP organic recurring revenue on constant currency basis(3) $ 274,287 $ 263,325 Non-GAAP organic recurring revenue growth on constant currency basis 4.2 % (1) Non-GAAP revenue from divested businesses excludes revenue associated with divested businesses in the prior period. The exclusion of the prior period revenue is to present the results of the divested business with the results of the combined company for the same period of time in both the prior and current periods. (2) Non-GAAP organic revenue and non-GAAP organic recurring revenue for the prior year periods presented herein may not agree to non- GAAP organic revenue and non-GAAP organic recurring revenue presented in the respective prior period quarterly financial information solely due to the manner in which non-GAAP organic revenue growth and non-GAAP organic recurring revenue growth are calculated. (3) To determine non-GAAP organic revenue growth and non-GAAP organic recurring revenue growth on a constant currency basis, revenues from entities reporting in foreign currencies were translated to U.S. Dollars using the comparable prior period's quarterly weighted average foreign currency exchange rates. The primary foreign currencies creating the impact are the Australian Dollar, British Pound, Canadian Dollar and Euro. Blackbaud, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (dollars in thousands) Three months ended March 31, 2026 2025 GAAP net income $ 31,139 $ 4,323 Non-GAAP adjustments: Add: Interest, net 14,357 15,290 Add: GAAP income tax provision 6,666 542 Add: Depreciation 2,206 2,975 Add: Amortization of intangibles from business combinations 6,855 7,586 Add: Amortization of software development costs(1) 12,421 11,872 Subtotal 42,505 38,265 Non-GAAP EBITDA $ 73,644 $ 42,588 Non-GAAP EBITDA margin(2) 26.2 % Non-GAAP adjustments: Add: Stock-based compensation expense $ 23,880 $ 22,170 Add: GCC workforce transition costs(3) 1,026 — Add: Acquisition and disposition-related costs(3) 147 25,132 Add: Security Incident-related costs — 2,180 Subtotal 25,053 49,482 Non-GAAP adjusted EBITDA $ 98,697 $ 92,070 Non-GAAP adjusted EBITDA margin(4) 35.1 % Rule of 40(5) 39.3 % Non-GAAP adjusted EBITDA $ 98,697 $ 92,070 Foreign currency impact on Non-GAAP adjusted EBITDA(6) (1,029) 205 Non-GAAP adjusted EBITDA on constant currency basis(6) $ 97,668 $ 92,275 Non-GAAP adjusted EBITDA margin on constant currency basis 35.0 % Rule of 40 on constant currency basis(7) 38.3 % (1) Includes amortization expense related to software development costs, and amortization expense from capitalized cloud computing implementation costs. (2) Measured by GAAP revenue divided by non-GAAP EBITDA. (3) See additional details in the reconciliation of GAAP to Non-GAAP operating income above. (4) Measured by non-GAAP organic revenue divided by non-GAAP adjusted EBITDA. (5) Measured by non-GAAP organic revenue growth plus non-GAAP adjusted EBITDA margin. See Non-GAAP organic revenue growth table above. (6) To determine non-GAAP adjusted EBITDA on a constant currency basis, non-GAAP adjusted EBITDA from entities reporting in foreign currencies were translated to U.S. Dollars using the comparable prior period's quarterly weighted average foreign currency exchange rates. The primary foreign currencies creating the impact are the Australian Dollar, British Pound, Canadian Dollar and Euro. (7) Measured by non-GAAP organic revenue growth on constant currency basis plus non-GAAP adjusted EBITDA margin on constant currency basis. (dollars in thousands) Three months ended March 31, 2026 2025 GAAP net cash provided by operating activities $ 51,459 $ 1,388 GAAP operating cash flow margin 18.3 % 0.5 % Non-GAAP adjustments: Less: purchase of property and equipment (1,668) (688) Less: capitalized software development costs (12,798) (12,970) Non-GAAP free cash flow $ 36,993 $ (12,270) Non-GAAP free cash flow margin 13.2 % (4.5) % SOURCE Blackbaud |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-04-29 09:25
2mo ago
|
Blackbaud (BLKB) Q1 Earnings and Revenues Surpass Estimates | FMP Stock News | |
|
Original source text
Blackbaud (BLKB - Free Report) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $0.96 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.56%. A quarter ago, it was expected that this software and services provider in the nonprofit sector would post earnings of $1.15 per share when it actually produced earnings of $1.19, delivering a surprise of +3.48%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Blackbaud, which belongs to the Zacks Computer - Software industry, posted revenues of $281.14 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.53%. This compares to year-ago revenues of $270.66 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Blackbaud shares have lost about 40.8% since the beginning of the year versus the S&P 500's gain of 4.3%. What's Next for Blackbaud?While Blackbaud has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Blackbaud was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.36 on $291.36 million in revenues for the coming quarter and $5.19 on $1.17 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Computer - Software is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Intuit (INTU - Free Report) , is yet to report results for the quarter ended April 2026. This maker of TurboTax, QuickBooks and other accounting software is expected to post quarterly earnings of $12.48 per share in its upcoming report, which represents a year-over-year change of +7.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Intuit's revenues are expected to be $8.52 billion, up 9.9% from the year-ago quarter. |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-04-29 10:11
2mo ago
|
Blackbaud, Inc. (BLKB) Q1 2026 Earnings Call Transcript | FMP Stock News | |
|
Original source text
Blackbaud, Inc. (BLKB) Q1 2026 Earnings Call Transcript |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-04-29 14:06
2mo ago
|
Blackbaud: 2026 Renewals Will Be The Major Test (Upgrade) | FMP Stock News | |
|
Original source text
Blackbaud: 2026 Renewals Will Be The Major Test (Upgrade) |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-05-04 09:00
2mo ago
|
Blackbaud Makes a Strategic Investment in Student First to Bring Stronger Connected Campus Experience to Higher Education Institutions | FMP Stock News | |
|
Original source text
Partnership Will Enable Higher Education Customers to Pair Student First's Future-Ready Student Information System with Blackbaud's Leading Financial Management and Fundraising Solutions to Unify Back-Office Operations and Power Student Success, /PRNewswire/ -- Blackbaud (NASDAQ: BLKB), the world's leading provider of AI-powered solutions for social impact, today announced a strategic investment in Student First, the provider of the most modern, AI-enabled student information system (SIS) designed to simplify administrative workflows and enhance the student experience for higher education institutions. With this investment, Blackbaud and Student First will deliver a best-in-class Connected Campus experience that reduces complexity and campus silos, unifying enrollment, financial aid, scholarships, advancement and finance into a single operating model. Blackbaud customers will be able to leverage Student First's flexible, student-centric SIS, which will natively integrate with Blackbaud's industry-leading solutions for financial management, fundraising, award management and payments to advance student success. "By joining forces with Student First, we're enabling college and university teams to connect the financial side of their operations to the student information side," said Mark Davis, vice president, education products, Blackbaud. "This kind of data flow creates a connected campus experience that ties student lifecycle activity to the dollars that fund it—linking student and donor activity through advancement, awards, and the general ledger—so institutions can operate smarter, strengthen stewardship, and have the visibility needed to align resources to fuel student success." "Student First was developed as a unified, cloud-native SIS for higher education, and this partnership with Blackbaud is a natural extension of that platform strength," said David Meek, CEO, Student First. "Together, we help institutions operate smarter in a challenging financial environment by strengthening stewardship, compliance, and long-term sustainability. Joint customers get a comprehensive technology suite built on industry-leading systems, and students get a single, seamless experience." Key Benefits of the Partnership: Student First brings a modern, AI-enabled, student-centric SIS, while Blackbaud delivers leadership in purpose-built fund accounting, fundraising, award management, and payments and billing solutions. The partnership connects student enrollment, tuition and donor activity directly to the general ledger, giving institutions a single view that provides greater visibility, accountability and confidence in financial decision-making. Blackbaud's Intelligence for Good® AI capabilities will bolster Student First's student-centric SIS to drive intelligent action across institutions. Institutions gain choice without compromise—modernizing their SIS while leveraging Blackbaud's trusted financial and advancement ecosystem. The two companies will collaborate on product direction and go-to-market strategy to expand and enhance how they serve higher education institutions. This connected campus model replicates the success Blackbaud has already achieved with its Total School Solution approach for independent K–12 schools, offering a complete suite of integrated products purpose built for the unique needs of education institutions. About Blackbaud Blackbaud (NASDAQ: BLKB) is the world's leading provider of AI-powered solutions for social impact. Serving nonprofits, educational institutions, companies committed to corporate social responsibility, and individual change makers, Blackbaud propels impact at scale with the sector's most intelligent solutions for fundraising and engagement, education solutions, financial management and CSR and grantmaking. With the deepest expertise powered by the world's largest philanthropic data set, the most connected workflows, and the most powerful impact network, Blackbaud's solutions are building a future where resources are unleashed at the speed of need. Blackbaud has been recognized by Fast Company, Newsweek, Quartz, Forbes and more for AI innovation, responsible leadership and workplace excellence. Blackbaud has operations in the United States, Australia, Canada, Costa Rica, India and the United Kingdom, supporting users in 100+ countries. Learn more at www.blackbaud.com or follow us on X/Twitter, LinkedIn, Instagram and Facebook. About Student First Student First is an AI-enabled, cloud-native Student Information System designed specifically for the full spectrum of higher education, from career colleges and community colleges to four-year institutions and online programs. Student First delivers a unified platform spanning recruiting and admissions, advising, academic operations, financial aid, student billing, and more. Institutions move beyond the limitations of legacy systems with a solution that simplifies operations, improves data accuracy, and surfaces actionable insight across every function. The result is less administrative burden, smarter decision-making, and a seamless experience for students at every stage of their journey. For more information visit www.studentfirst.com. Media Inquiries [email protected] Forward-looking Statements Except for historical information, all of the statements, expectations and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties, including statements regarding expected benefits of products and product features. Although Blackbaud attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors that could cause results to differ materially include the following: general economic risks; uncertainty regarding increased business and renewals from existing customers; continued success in sales growth; management of integration of acquired companies and other risks associated with acquisitions; risks associated with successful implementation of multiple integrated software products; the ability to attract and retain key personnel; risks associated with management of growth; lengthy sales and implementation cycles; technological changes that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for Blackbaud, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from Blackbaud's investor relations department. All Blackbaud product names appearing herein are trademarks or registered trademarks of Blackbaud, Inc. SOURCE Blackbaud |
|||
|
Saved
2026-06-12 16:12
1mo ago
Published
2026-05-15 10:30
2mo ago
|
Blackbaud's Latest Product Innovations Reflect Company's Defensible Market Position; Anchored in Data, Context, and Trust | FMP Stock News | |
|
Original source text
Trusted AI Engine Unites Horizontal Coherence with Vertical Intelligence for Enduring AI Value in the Social Impact Sector, /PRNewswire/ -- Blackbaud (NASDAQ: BLKB), the world's leading provider of AI-powered solutions for social impact, announced a series of product innovations this week that reflect the company's belief that durable leadership in the AI era will be defined not by standalone features or generic AI, but by intelligent systems that are deeply embedded, difficult to replicate, and trusted to act. With decades of proprietary data, purpose‑built workflows, and extensive sector expertise, Blackbaud is extending the strategic relevance of its platforms as customer expectations shift from insight to execution. "Leadership in AI will not be defined by how much intelligence a system can generate, but by how confidently users are willing to act on it," said Mike Gianoni, president, CEO and vice chairman of the board of directors of Blackbaud. "In social impact, trust is foundational. That's why we're putting responsible AI principles at the center of everything we do; making sure Blackbaud AI is designed with unmatched context, clear guardrails, and consistent human oversight so innovation accelerates impact rather than introducing risk." As AI reshapes the software industry, Gianoni is advancing a clear point of view on where lasting advantage will reside: the company is building its next era of solutions as an AI engine that combines Blackbaud's data and context moats to propel better outcomes for customers, resulting in the ultimate differentiator: a trust moat. As trust increases, individuals and organizations become more comfortable shifting from acting themselves to letting Blackbaud AI act with them, or for them, under clear direction and guardrails. At the sector-wide level, the Blackbaud Verified Network has built a layer of trust by reducing friction and increasing the speed and transparency of connection across the sector. "When technology earns trust, it changes what's possible," Gianoni said. "That's the future we're building toward—one where insight, context, and choice come together to help the people changing the world move faster and achieve outcomes that were previously out of reach." Across its portfolio, Blackbaud's recent innovations demonstrate this strategy in action by embedding AI directly into systems of record to move organizations from insight to execution: The Development Agent, the first of Blackbaud's Agents for Good™ introduced to U.S. Raiser's Edge NXT® customers earlier this year, represents a new class of purpose‑built, autonomous AI agents embedded directly in a social impact system of record. Development Agent expands fundraising team capacity to engage one-on-one with thousands of donors via email and text messages, which can increase affinity and giving. Capabilities such as Chat for Blackbaud AI embed conversational, context‑aware intelligence across Blackbaud's core solutions, enabling users to move from insight to action within the platform itself by surfacing insights, summarizing key information, suggesting next steps, and generating communication drafts. By keeping decision‑making and execution inside the system of record, these experiences reduce daily friction and deepen customer engagement. Across financial management and fundraising, Blackbaud is applying AI to expand operating leverage without introducing unnecessary governance risk. From automating high‑volume document workflows to delivering adaptive, data‑driven fundraising insights through Prospect Insights Pro, these capabilities improve efficiency and decision quality while supporting scale in complex, regulated operating environments. In the education space, Blackbaud is introducing AI-powered capabilities designed to improve outcomes without scaling workload or staffing levels with features like Blackbaud Billing Management™ Collections Assistant, designed to help schools take a more proactive, thoughtful approach to collections while preserving strong family relationships. Beyond individual customer workflows, Blackbaud continues to invest in ecosystem‑level efficiency through innovations like Expedited Giving, which can disburse corporate employee giving to recipient nonprofits in just hours (up to 95% faster than alternatives in the market), enhancing trust across the giving lifecycle and extending Blackbaud's role as a critical connector in the social impact economy. Together, these advances underscore Blackbaud's conviction that enduring AI value will be created by platforms that combine breadth and depth—horizontal reach and vertical intelligence—within trusted systems organizations depend on to operate. By anchoring innovation in data, context, and trust, Blackbaud is positioning its solutions to remain essential as the AI landscape evolves. A full list of recently announced product updates is available on the Blackbaud Newsroom. About Blackbaud Blackbaud (NASDAQ: BLKB) is the world's leading provider of AI-powered solutions for social impact. Serving nonprofits, educational institutions, companies committed to corporate social responsibility, and individual changemakers, Blackbaud propels impact at scale with the sector's most intelligent solutions for fundraising and engagement, education solutions, financial management and CSR and grantmaking. With the deepest expertise powered by the world's largest philanthropic data set, the most connected workflows, and the most powerful impact network, Blackbaud's solutions are building a future where resources are unleashed at the speed of need. Blackbaud has been recognized by Fast Company, Newsweek, Quartz, Forbes and more for AI innovation, responsible leadership and workplace excellence. Blackbaud has operations in the United States, Australia, Canada, Costa Rica, India and the United Kingdom, supporting users in 100+ countries. Learn more at www.blackbaud.com or follow us on X/Twitter, LinkedIn, Instagram and Facebook. Media Inquiries [email protected] Forward-looking Statements Except for historical information, all of the statements, expectations and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties, including statements regarding expected benefits of products and product features. Although Blackbaud attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors that could cause results to differ materially include the following: general economic risks; uncertainty regarding increased business and renewals from existing customers; continued success in sales growth; management of integration of acquired companies and other risks associated with acquisitions; risks associated with successful implementation of multiple integrated software products; the ability to attract and retain key personnel; risks associated with management of growth; lengthy sales and implementation cycles; technological changes that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for Blackbaud, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from Blackbaud's investor relations department. All Blackbaud product names appearing herein are trademarks or registered trademarks of Blackbaud, Inc. SOURCE Blackbaud |
|||